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translational gap is partially explained by a lack of understanding of the function of time and circadian timing in
the complex neurobiology around ketamine. Indeed, the acute pharmacological effects of a single ketamine treat-
ment last for only a few hours, whereas the antidepressant effects peak at around 24 hours and are sustained for
the following few days. Numerous studies have investigated the acute and long-lasting neurobiological changes
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The discovery of the antidepressant effects of ketamine, an N-
methyl-D-aspartate receptor (NMDAR) antagonist, has been an impor-
tant breakthrough in psychiatry. Whereas weeks of continuous
treatment are required for the conventional antidepressant drugs (e.g.,
fluoxetine, a serotonin-selective reuptake inhibitor) to produce their
full therapeutic effects (Rush et al., 2006), ketamine alleviates the core
symptoms of depression and suicidal ideation within only a few hours
(Aan Het Rot, Zarate, Charney, & Mathew, 2012; Pennybaker, Niciu,
Luckenbaugh, & Zarate, 2017). Remarkably, ketamine has also demon-
strated rapid therapeutic efficacy in certain other psychiatric disorders,
including post-traumatic stress disorder (Feder et al., 2014) and obses-
sive compulsive disorder (Rodriguez et al., 2013; Rodriguez, Kegeles,
Flood, & Simpson, 2011). Last year, the S(+)-enantiomer of ketamine
(esketamine) (Zheng et al., 2020) was approved by the US Food and
Drug Administration and the EuropeanMedicines Agency as an adjunc-
tive treatment for high-suicide-risk, depressed patients to provide faster
symptomatic relief. The market entry of esketamine as an intranasal
product is expected to increase the use of ketamine in psychiatry, and
it has already been included in the depression treatment guidelines, at
least in Finland. However, a significant proportion of patients do not
get sufficient benefit from ketamine (Aan Het Rot et al., 2012). More-
over, the antidepressant effects of ketamine are transient and com-
monly persist for only up to a week (Aan Het Rot et al., 2012; Coyle &
Laws, 2015; Newport et al., 2015; Pennybaker et al., 2017). Therefore,
understanding the neurobiological basis of ketamine’s antidepressant
effects is essential to improve the treatment protocols and to develop
therapies that more reliably lead to rapid and sustained antidepressant
effects.
We begin this review by briefly outlining certain effects and mecha-
nisms considered to be important for ketamine’s antidepressant action.
Althoughmechanistic studies have identified specificmolecular interac-
tions, signaling cascades, synaptic changes, and certain metabolic
byproducts of ketamine to be necessary and sufficient for ketamine’s
antidepressant effects in animals, such insights have not been efficiently
translated into clinical treatments.We believe that this translational gap
is related to a traditional mindset, wherein ketamine’s effects are pre-
dominantly explained by basic pharmacological principles and incon-
spicuous disregard of intrinsic physiology. However, the acute
pharmacological effects of ketamine last only a fewhours,while its ther-
apeutic effects persist long thereafter. Notably, the antidepressant ef-
fects typically peak around 24 hours after a single dose of ketamine
(Aan Het Rot et al., 2012; Berman et al., 2000; Coyle & Laws, 2015;
Kishimoto et al., 2016; Zarate Jr et al., 2006).We believe that it is impor-
tant to view the actions of ketamine through a neurobiological perspec-
tive, which better appreciates the most fundamental aspects of the
circadian physiology of humans. To this end,we discuss the basic neuro-
biology and function of sleep and circadian rhythm, with a special em-
phasis on features previously associated with the antidepressant
effects of ketamine. Finally, we discuss how recently proposed hypoth-
eses of rapid antidepressant action, which focus on sleep and chronobi-
ology, may provide critical and more comprehensive insights into the
actions of rapid-acting antidepressants in the brain.
2. Antidepressant mechanisms of ketamine
Themain pharmacological effects of ketamine aremediated through
the blockade of NMDARs, which are Na+/Ca2+/K+ permeable channels
activated by the principal excitatory neurotransmitter glutamate. Keta-
mine also targets various other receptors and channels, and inhibits
monoamine reuptake (for a thorough review of ketamine’s pharmacol-
ogy, see Zanos et al., 2018). The effects of ketamine are dose dependent,
with the higher end of the range producing a significant blockade of ex-
citatory neurotransmission, ultimately leading to dissociative anesthe-
sia and loss of consciousness. In the treatment of depression, ketamine2
is commonly used at lower subanesthetic doses, administered either
via a slow intravenous infusion or intranasally. Notably, both in rodents
and humans, these subanesthetic doses increase cortical excitation and
energymetabolism(Abdallah et al., 2018; Abdallah, Sanacora, Duman,&
Krystal, 2018; Breier, Malhotra, Pinals, Weisenfeld, & Pickar, 1997; Li et
al., 2016; Lu et al., 2008), which contradicts the anticipated effects of an
NMDAR-blocking agent.
The disinhibition hypothesis explains the paradoxical excitatory ef-
fects of subanesthetic ketamine through the blockade of NMDARs on
gamma-aminobutyric acid (GABA)-ergic interneurons, leading to the
disinhibition of pyramidal neurons, accompanied by enhanced gluta-
mate release and burst (Abdallah, Sanacora, et al., 2018; Homayoun &
Moghaddam, 2007; Miller, Moran, & Hall, 2016; Zanos & Gould, 2018).
Two recent animal studies provide strong support for this hypothesis
(Ali et al., 2020; Widman & McMahon, 2018). Among other putative
(or complementary) mechanisms, ketamine has been proposed to di-
rectly antagonize the extrasynaptic NMDARs on pyramidal neurons
(Abdallah, Sanacora, et al., 2018; Miller et al., 2016; Zanos & Gould,
2018) and to block NMDAR-mediated spontaneous neurotransmission
(Autry et al., 2011).Moreover, animal studies suggest that ketamine ex-
erts NMDAR inhibition-independent antidepressant actions via its
hydroxynorketamine metabolites (HNKs; especially 2R,6R-HNK)
(Zanos et al., 2016). This hypothesis is not, however, unequivocally sup-
ported by preclinical data (Yamaguchi et al., 2018; Yang et al., 2017).
Furthermore, recent clinical studies have observed a negative - rather
than a positive - correlation with the plasma levels of 2R,6R-HNK and
antidepressant and antisuicidal effects of ketamine (Farmer et al.,
2020; Grunebaum et al., 2019).
Most hypotheses about ketamine’s antidepressant action ultimately
converge on its ability to activate postsynaptic α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptors (AMPARs) through a gluta-
mate burst (Koike, Iijima, & Chaki, 2011; Li et al., 2010; Maeng et al.,
2008). In linewith this notion, pre- and cotreatmentwith an AMPAR in-
hibitor blocks the antidepressant-like behavioral effects of ketamine in
rodents (Autry et al., 2011; Li et al., 2010; Maeng et al., 2008). The keta-
mine metabolite HNK also promotes glutamate release and AMPAR ac-
tivation in mice (Pham et al., 2018), effects that may arise – at least in
part – through the blockade of presynaptic metabotropic glutamate re-
ceptor subtype 2 (mGlu2) inhibitory autoreceptors (Zanos et al., 2019).
Notably, AMPAR-positive allosteric modulators exhibit antidepressant
effects; – however, their therapeutic effects may need chronic adminis-
tration (Mendez-David et al., 2017; Nations et al., 2012; Shen et al.,
2019), implying that their effects more closely resemble those of con-
ventional antidepressants.
The ketamine-induced activation of AMPARs is associated with sev-
eral important molecular pathways implicated in antidepressant ac-
tions. Most importantly, ketamine evokes the rapid translation and
release of brain-derived neurotrophic factor (BDNF) (Autry et al.,
2011; Lepack, Bang, Lee, Dwyer, & Duman, 2016), a neurotrophin
known for its pivotal role in synaptic plasticity (Park & Poo, 2013;
Song, Martinowich, & Lee, 2017) and antidepressant effects (Castrén,
Võikar, & Rantamäki, 2007; Duman, Heninger, & Nestler, 1997). Keta-
mine also increases the phosphorylation of the BDNF receptor TrkB
(Autry et al., 2011; Sun et al., 2016); however, these effects are most
prominent with high (sedative-anesthetic) doses (Kohtala et al.,
2019). Nevertheless, the antidepressant-like effects of subanesthetic ke-
tamine and several novel, putative, rapid-acting antidepressants are di-
minished in BDNFmet66met knock-in mice that exhibit compromised
activity-dependent BDNF release (Fukumoto et al., 2019; Ghosal et al.,
2018; Kato et al., 2018; Liu et al., 2012). It has been suggested that,
through its effects on BDNF-TrkB signaling, ketamine utilizes molecular
mechanisms that ultimately reverse synaptic deficits and thereby alter
network activity – features implicated in the pathophysiology of de-
pression (Duman & Aghajanian, 2012).
Downstream of TrkB, mammalian target of rapamycin (mTOR) and
extracellular signal-regulated kinase 1/2 (ERK1/2, also known as p44/
S. Kohtala, O. Alitalo, M. Rosenholm et al. Pharmacology & Therapeutics 221 (2021) 10774142-mitogen-activated protein kinase [p44/42-MAPK]) signaling along
with the inhibition of glycogen synthase kinase 3β (GSK3β) are consid-
ered important for ketamine’s antidepressant action (Autry et al., 2011;
Autry & Monteggia, 2012; Beurel, Song, & Jope, 2011; Duman &
Aghajanian, 2012; Dwyer, Maldonado-Avilés, Lepack, DiLeone, &
Duman, 2015; Rantamäki & Yalcin, 2016; Réus et al., 2014). Moreover,
ketamine increases the transcription of immediate-early genes (IEGs),
such as Homer-1a, which further contribute to glutamatergic signaling
and synaptic function (De Bartolomeis et al., 2013; Ficek et al., 2016).
Notably, in rodents, the upregulation of Homer-1a in association with
the onset of antidepressant-like effects are a common feature of several
antidepressant treatments (Holz et al., 2019; Serchov et al., 2015). BDNF
up-regulates Homer-1amRNA and its protein accumulation at synapses
in cultured neurons, presumably through the ERK pathway (Ji et al.,
2010; Kato, Fukazawa, Ozawa, Inokuchi, & Sugiyama, 2003; Sato,
Suzuki, & Nakanishi, 2001). The ketamine-induced increase in syn-
apse-associated proteins and dendritic spine formation are causally as-
sociated with increased mTOR activity (Duman & Aghajanian, 2012; Li
et al., 2010). Indeed, in rodents, the blockade of mTOR signaling with
rapamycin abolishes ketamine-induced synaptogenesis along with the
associated antidepressant-like behavioral responses (Li et al., 2010; Li
et al., 2011). However, a recent study suggests that the increase in pre-
frontal cortical spine formation is not required for the rapid effects of ke-
tamine on animal behavior or circuit function but may instead
contribute to the sustained antidepressant effects (Moda-Sava et al.,
2019). The interpretation of these findings and the specific role of
mTOR in ketamine’s antidepressant actions are complicated by a recent
clinical study, inwhich rapamycin pretreatment – in contrast to the pre-
dicted results – prolonged the antidepressant effects of ketamine
(Abdallah et al., 2020).
Taking into consideration the direct involvement of the above-
mentioned effectors in both – early and late – phases of long-term
potentiation (LTP; for review, see Baltaci, Mogulkoc, & Baltaci,
2019), ketamine is expected to affect synaptic plasticity. Indeed,
studies employing animal models of depression, such as chronic
mild stress, have demonstrated the impairment of hippocampal
LTP (Alfarez, Joëls, & Krugers, 2003; Pavlides, Nivón, & McEwen,
2002), which may be restored by ketamine-induced facilitation of
BDNF signaling and synaptic plasticity (Ma et al., 2017; Nosyreva et
al., 2013; Sun et al., 2016; Zhou et al., 2014). Several studies also sup-
port the notion of impaired LTP-like plasticity in depressed patients
(Kuhn et al., 2016; Normann, Schmitz, Fürmaier, Döing, & Bach,
2007; Player et al., 2013) and the ability of ketamine to enhance
LTP-mediated neural plasticity (Nugent, Wills, Gilbert, & Zarate,
2019; Sumner et al., 2020). Here, increased neural activation is likely
the first step towards synaptic change, as demonstrated in rodent
studies in which ketamine administration into the infralimbic pre-
frontal cortex or the optogenetic activation of this area induces anti-
depressant-like behavioral responses, whereas prior neuronal
inactivation with the GABAA agonist muscimol blocks these effects
(Fuchikami et al., 2015). Similarly, the delivery of neutralizing
BDNF antibodies into the medial PFC (mPFC) blocks ketamine’s
antidepressant-like effects (Lepack, Fuchikami, Dwyer, Banasr, &
Duman, 2014). More recent rodent studies indicate that the
optogenetic stimulation of dopamine receptor 1 expressing pyrami-
dal neurons in the mPFC is sufficient to produce antidepressant-like
effects comparable to those of ketamine (Hare et al., 2019).
As demonstrated by this brief overview, the knowledge of
ketamine’s many effects at various levels is increasing at an astonish-
ing rate. In the following chapters, we discuss how many of the ef-
fects associated with ketamine’s antidepressant actions, such as3
cortical excitation, synaptogenesis, and involved molecular determi-
nants, are physiological events that have a reciprocal connection
with wake and sleep. To ensure a good understanding of the topic,
we first introduce the basic neurobiology and functions of circadian
rhythm and sleep.3. A primer for time and timing
3.1. Introduction to circadian rhythms and sleep
Animals adjust and coordinate their behavior according to the circa-
dian (Lat. circa, approximately; Lat. dies, day) rhythms generated by cir-
cadian oscillators throughout the body (INFOBOX). The circadian
regulation has evolved as an adaptation to temporally align behaviors
to the availability of light and nutrients, reflecting the day/night cycle
generated by the rotation of the Earth. A multitude of physiological pro-
cesses, such as body temperature, liver metabolism, energy metabolism,
bloodpressure, urine production, andneuroendocrine function showcir-
cadian rhythmicity (Bass & Takahashi, 2010; Takahashi & Zatz, 1982).
Mammalian circadian regulation is hierarchical and comprises a master
clock, located in the hypothalamic suprachiasmatic nucleus (SCN), and
peripheral clocks, the circadian activity of which is coordinated by the
master clock (Moore & Eichler, 1972; Stephan & Zucker, 1972;
Yamazaki, 2000; Yoo et al., 2004). The master clock is synchronized to
the surrounding environment primarily through photic input from the
retina (Challet, Caldelas, Graff, & Pévet, 2003; Pickard, 1980), along
with several non-photic inputs related tometabolic activity and vigilance
states (Abrahamson & Moore, 2001; Janik & Mrosovsky, 1994; Krout,
Kawano, Mettenleiter, & Loewy, 2002; Moga & Moore, 1997; Morin &
Allen, 2006), as well as through an endocrine feedback loop mediated
by melatonin (Lavie, 1997). The SCN is composed of synchronized en-
sembles of highly interconnected GABA- and peptidergic neurons, mak-
ing its oscillations resilient to perturbations resulting from misaligned
internal and external cues (Hastings & Herzog, 2004; Liu et al., 2007).
In contrast, with a few exceptions, the non-SCN oscillators generally
maintain their circadian rhythmicity only in the presence of synchroniz-
ing cues from the SCN (Abe et al., 2002) and are also responsive to local
cues related to tissue function (Richards &Gumz, 2012). Notably, the lat-
eral habenula is directly connected to the SCN and may display both in-
trinsic oscillations and direct responses to retinal light (Langel, Ikeno,
Yan, Nunez, & Smale, 2018; Mendoza, 2017; Riemann, Krone, Wulff, &
Nissen, 2020). At the molecular level, cells generate an approximately
24-hour rhythmicity in response to synchronizing cues by a complex ar-
chitecture of interlocking positive and negative feedback loops of circa-
dian gene transcription and translation (Partch, Green, & Takahashi,
2014; Takahashi, 2017). The INFOBOX provides a more comprehensive
description of the molecular machinery of circadian clockwork. In brief,
the cues received by the circadian clocks are relayed primarily through
excitatory glutamatergic neurotransmission. Once the cells receive a
cue, various Ca2+-based signaling pathways are activated, eventually
leading to the activation of Ca2+/cAMP response element-binding pro-
tein (CREB). Subsequently, CREB initiates transcription of various IEGs
and clock-controlled genes, possibly resulting in secondary effects
throughout the body as systemic signals pass information between indi-
vidual clocks. The combined synchronized output of the circadian clocks,
residing virtually in every tissue throughout the body, enables the organ-
ism to anticipate the imminent rhythmic changes in the environment
(e.g., light and nutrients) and match them with the appropriate local
gene and protein output, eventually resulting in systemic responses
(e.g., vigilance states and metabolism).
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the intracellular pathways entraining the mammalian circadian clock.
The central pacemaker in the suprachiasmatic nucleus (SCN) aligns
its circadian fluctuations of gene transcription and translation primarily
on the basis of photic input relayed from the retina via excitatory glu-
tamatergic neurotransmission. A light pulse results in an influx of Ca2
+ into SCN neurons, primarily through the N-methyl-D-aspartate re-
ceptors (NMDAR). The same intracellular pathways are also evoked
by other means of altering the intracellular Ca2+ concentration, includ-
ing uptake through voltage-gated calcium channels (VGCC) and mobi-
lization of intracellular Ca2+ stores. Individual SCN neurons receive
additional network input through various G-protein coupled receptors
(GPCR; e.g., vasoactive intestinal peptide [VIP], and γ-aminobutyric
acid [GABA]) with varying effects on neuronal excitation depending
on receptor and ligand. Through a set of kinases, especially extracellu-
lar signal-regulated kinase 1/2 (ERK1/2), the pathways affected by in-
coming signals eventually result in the activation of Ca2+/cAMP
response element binding protein (CREB) to promote the transcription
of immediate-early genes (e.g. c-Fos, Bdnf) and clock-controlled
genes, leading to altered function and output of the circadian clock.
Periodic oscillatory activity of the circadian clockwork arises from the
cyclical fluctuations in the levels of circadian locomotor output cycles
kaput (CLOCK) and brain and muscle ARNT-like 1 (BMAL1) that initi-
ate the transcription and translation of period (Per1–3) and
cryptochrome (Cry1–2) genes. Levels of PER and CRY proteins peak
in the daytime to provide negative feedback to CLOCK-BMAL1 activ-
ity, thereby suppressing their own transcription. During the subse-
quent night, PER and CRY degrade gradually, relieving the inhibitory
effect on CLOCK-BMAL1 and allowing a new cycle of transcription
to begin ~24 hours after the last onset. A second, stabilizing loop is
formed by CLOCK-BMAL1-induced transcription of retinoic acid-re-
lated orphan nuclear receptor genes – reverse-erythroblastosis virus
and retinoic acid receptor-related orphan receptors (Rorα/β). Translated
REV-ERB and ROR proteins repress and promote the transcription of4
Bmal1, respectively, and reinforce the oscillatory activity of the core
loop. Both spatial (nuclear and cytoplasmic localization of clock pro-
teins) and temporal (production and degradation rate) dynamics of
the circadian clockwork are mainly post-transcriptionally regulated.
The approximately 24-hour periodicity is determined by the rate of
clock protein degradation resulting from an interplay of various post-
translational modifications, including phosphorylation (e.g., casein ki-
nases [CKIε/δ and CKII], glycogen synthase kinase 3 β [GSK3β], and
adenosine monophosphate-activated kinase [AMPK]), ubiquitination
(e.g., β-TrCP1/2 and FBXL3/21), acetylation, and SUMOylation. The
degradation rate is slowed by phosphatases (PP1/5), which dephos-
phorylate the clock components making them unavailable for degrada-
tion. In addition, the circadian clocks receive additional modulatory
input regarding metabolic activity via pathways including AMPK, mam-
malian target of rapamycin (mTOR), and sirtuin-1 (SIRT1) signaling. B.
The SCN relays its circadian entraining information to the peripheral
clocks using humoral signals (e.g., cortisol and melatonin), autono-
mous nervous system, body temperature, and feeding-related cues.
The peripheral clocks transmit back reciprocal input based on the envi-
ronmental variables they are tracking, including nutrient availability,
environmental temperature, physical activity, and social interaction.
While the overall mechanism of the clock is conserved across both
central and peripheral oscillators, the peripheral clocks differ in their
tissue-specific variations of molecular architecture. Compared to the
SCN, which can hold the regular circadian rhythmicity for extended pe-
riods even in absence of light, most of the peripheral oscillators lose
their rhythmicity rapidly when the SCN output is arrhythmic or ab-
lated. Together, the orchestra of circadian oscillators throughout the
body produce a complex interplay of time-of-day-dependent cyclic
changes that affect most functions, ranging from biochemistry to be-
havior and mood. Based on the following articles: Astiz, Heyde, &
Oster, 2019; Gallego & Virshup, 2007; Herzog & Tosini, 2001;
Hirano, Fu, & Ptáček, 2016; Stojkovic, Wing, & Cermakian, 2014;
Travnickova-Bendova, Cermakian, Reppert, & Sassone-Corsi, 2002.
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biological markers, we humans also experience an indisputable
rhythm every day: the sleep-wake cycle. Sleep is a fundamental be-
havioral state preserved across phylogeny, indicating that it serves
an essential biological function in all animals (Anafi, Kayser, &
Raizen, 2019). It can be defined as a state of behavioral inactivity
that typically occurs at a species-specific time of day. According to
the widely accepted two-process model of sleep regulation
(Borbély, 1982), the onset of sleep is influenced by homeostatic
and circadian components, Process S and Process C, respectively
(Fig. 1). During the time spent awake, homeostatic sleep pressure
builds up and drives the brain to fall asleep (Achermann, Dijk,
Brunner, & Borbély, 1993; Borbély, Baumann, Brandeis, Strauch, &
Lehmann, 1981). The homeostatic mechanisms have been systemat-
ically studied using sleep deprivation (SD), in which prolonged
wakefulness increases the homeostatic pressure and the need for re-
covery sleep. Based on the daily rhythms and routines, homeostatic
and circadian factors are commonly aligned to promote sleep to-
wards the end of a day of wakefulness or activity. However, under
high sleep pressure, the need for recovery sleep can override circa-
dian regulation to promote sleep regardless of circadian misalign-
ment. Conversely, circadian regulation helps one to feel alert and
energetic in the morning even if they have not slept at all. (See
Infobox.)
In the mammalian brain, sleep can be broadly divided into two
discrete stages that exhibit distinct baseline brain activity measured
by electroencephalography (EEG): rapid eye movement (REM) andFig. 1. Two-processmodel of sleep regulation. The timing of sleep and need for sleep are determ
the two processes is demonstrated inA,whereas B highlights the cyclic nature of homeostatic sle
debt, which accumulates as a function of wake duration and decreases as deep sleep progresse
align the optimal level of arousal and metabolism with the surrounding environmental condit
physical and social activity. The optimal sleep window emerges when the level of sleep press
occurring towards the end of the light period in humans. Towards morning, when enough
promote arousal again, waking occurs. Prolonged wake (e.g., sleep deprivation) produces in
subjective sleepiness declines after a night of wakefulness owing to the arousal-promot
complementary effects. Strong synaptic potentiation during daytime leads to increased c
excitability conditions for potentiation to occur.
5
non-REM (NREM) sleep (Pace-Schott & Hobson, 2002). REM sleep
consists of wake-like high-frequency, low-amplitude EEG activity,
along with decreased muscle tone as measured by electromyogra-
phy. It is also called paradoxical sleep owing to its close resemblance
to waking EEG activity. In contrast, NREM sleep in humans is divided
into three stages that are dominated by high-amplitude, synchro-
nized, low-frequency EEG activity (0.5–4.0 Hz, delta). This slow-
wave activity (SWA) is most prominent during the deepest stage
(stage III), named aptly as slow-wave sleep (SWS). From the begin-
ning of a sleep period, NREM and REM sleep emerge in alternating
patterns during four to five sleep cycles that occur each night in
adult humans. Typically, the first sleep cycle of the night displays a
longer duration of deeper NREM sleep, whereas the period of REM
sleep is shorter. In the following sleep cycles, the duration of NREM
sleep gets progressively shorter while the proportion of REM sleep
increases. This characteristic pattern of sleep organization varies in
different species and subjects. Notably, both NREM and REM sleep
are homeostatically regulated in all animals. After SD, the time
spent in SWS and its intensity increases (Fig. 1). Similarly, after
REM sleep deprivation, the time spent in REM sleep increases during
the subsequent sleep period.
The electrophysiological rhythms of sleep are unequivocally gener-
ated by the principal computational components of the brain – neural
circuits and neurons. Apart from neurons, glial cells are major contribu-
tors to the maintenance, regulation, and function of sleep. Glial cells
have important roles in metabolic and energetic processes, function of
the glymphatic system, regulation of immune functions, and processesined by process C and process S, respectively (Borbély, 1982). The complementarynature of
ep drive during regular sleep-wake cycles. Process S represents sleephomeostasis, or sleep
s. Process C, in contrast, exhibits oscillations with an approximately 24-hour periodicity to
ions. The timing of the cycle is synchronized to salient cues including light, nutrients, and
ure has grown sufficient and the circadian arousal-promoting drive has subsided, usually
sleep pressure has been relieved during sleep and the new cycle of process C begins to
creased sleep pressure and need for recovery sleep. During this extended wakefulness,
ing effects of process C. While distinct, the two processes are inseparable and have
lock entrainment and vice versa – an entrained clock during the day enables optimal
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dian rhythms, see Artiushin & Sehgal, 2020).
3.2. Functions of sleep
Despite great advances in the understanding of the complexity of
sleep and its molecular, cellular, and functional substrates, its primary
physiological functions remain unclear (Krueger, Frank, Wisor, & Roy,
2016). Sleep serves multiple functions ranging from conservation of en-
ergy, restoration of energy supplies, recovery from cellular stress, repair
of cellular and DNA damage, removal of metabolic byproducts via con-
vective cerebrospinal fluid flow, modulation of the immune system,
and regulation of temperature and metabolism (Bass & Takahashi,
2010; Bellesi, Bushey, Chini, Tononi, & Cirelli, 2016; Benington & Heller,
1995; Inokawa et al., 2020; Mackiewicz et al., 2007; Refinetti &
Menaker, 1992; Reimund, 1994; Scharf, Naidoo, Zimmerman, & Pack,
2008; Xie et al., 2013; Zada, Bronshtein, Lerer-Goldshtein, Garini, &
Appelbaum, 2019). Disturbed and insufficient sleep is associated with
various disorders affecting metabolic (Spiegel, Leproult, & Van Cauter,
1999), cardiovascular (Gangwisch et al., 2006), and immunological func-
tions (Bryant, Trinder, & Curtis, 2004); however, many of these functions
may also be addressed, to a certain degree, during wakefulness or quiet
rest without the requirement for the evolutionarily risky disconnection
from the external environment that occurs during sleep. Thus, it can be
argued that the activity that occurs in the brain during sleep-induced un-
consciousness is the key to understanding the primary functions of sleep.
Remarkably, sleep duration and intensity are closely associated with
brain size across species, and the depth and proportion of NREM sleep
varies during different brain development stages. NREMsleep peaks dur-
ing brain growth spurt and declines during adolescence (Feinberg &
Campbell, 2010). It has been argued that NREM sleep during develop-
ment is causally associated with brain maturation and reorganization
of neuronal networks driven by synaptic elimination (Feinberg &
Campbell, 2010). Indeed, the duration of NREM sleep declines with age
as the sleep generally becomes more fragmented and circadian rhyth-
micity is reduced (Fogel et al., 2012).Moreover, sleep serves as a suitable
period for the regulation of synaptic strength, memory consolidation,
and learning (Stickgold, 2005). Increasedmemory retention iswidely at-
tributed to the function of sleep, as it markedly enhances both memory
encoding and consolidation (Walker & Stickgold, 2006). Adequate
sleep before memory formation, and conversely, sufficient sleep after
it, support information storage in long-term memory (Diekelmann &
Born, 2010; Mander, Santhanam, Saletin, & Walker, 2011; Walker,
2009). In contrast, disturbed and insufficient sleep is associated with
the impairment of multiple cognitive domains (Durmer & Dinges,
2005; Van Dongen,Maislin, Mullington, & Dinges, 2003) and susceptibil-
ity to psychiatric disorders such as major depression (Benca, 1992; Nutt,
Wilson, & Paterson, 2008; Ohayon & Roth, 2003; Riemann, Berger, &
Voderholzer, 2001; Tsuno, Besset, & Ritchie, 2005) (see Chapter 3.3).
However, there is controversy regarding how many beneficial effects
sleep may have and what neurobiological functions the different stages
of sleep may promote. Although it is commonly accepted that neural
plasticity occurs both duringwakefulness and sleep, the overall contribu-
tion to synaptic change and synaptic plasticity remains unclear.
It has been proposed that neuroplastic changes initiated during the
encoding of waking experience trigger transient changes and prime cir-
cuits and synapses to undergo further processing in sleep (Seibt & Frank,
2019). For example, in the hippocampus, firing sequences correspond-
ing to particular experienced events during wakefulness can be
reactivated during SWS and primed synapsesmay undergo protein syn-
thesis-dependent changes that support structural modifications re-
quired for long-term information storage. Sleep may also serve a role
in the active system consolidation of memory by redistributing newly
encoded memory engrams, for example, from the hippocampus to the
cortex (Born & Wilhelm, 2012). Moreover, recent studies suggest that
dendritic spines in layer V pyramidal neurons of the motor cortex are6
influenced by both REM and NREM sleep. In particular, REM sleep is as-
sociated with the selective pruning and maintenance of new dendritic
spines following motor learning (Li, Ma, Yang, & Gan, 2017), whereas
the reactivation of neurons following motor learning in NREM sleep is
involved in the facilitation of spine formation (Yang et al., 2014). Further
research is required to thoroughly investigate howdifferent sleep stages
ultimately affect spine dynamics; nevertheless the above-mentioned
studies highlight the important connection between sleep and the reg-
ulation of synaptic function. To make things more complicated, mecha-
nisms of plasticity duringwake and sleepmay vary between areas of the
brain, subtypes of neurons, and types of memory and learning. Many of
the proposed hypotheses are not mutually exclusive, and ultimately
many different processes likely contribute to the synaptic changes asso-
ciated with sleep.
Many hypotheses examining the role of sleep in memory consolida-
tion and facilitation of synaptic plasticity focus on SWS and SWA – also
regarded as markers of sleep intensity. The amount and intensity of
sleep SWA are strongly correlated with cortical activity during the pre-
vious wakeful period. This is particularly demonstrated by the pro-
nounced increase in SWA during recovery sleep after SD (Huber,
Deboer, & Tobler, 2000) (Fig. 1). The connection between cortical activ-
ity and SWA can also be observed on the level of cortical microcircuits
(Tononi & Cirelli, 2014). This is exemplified by studies utilizing a hand
motor coordination task or arm immobilization, which are mirrored
by increased and decreased SWA, respectively, in the corresponding
cortical areas during sleep (Huber et al., 2006). Skilled reaching tasks
in rats and repetitive transcranialmagnetic stimulation and somatosen-
sory stimulation in humans also lead to increased SWA during the sub-
sequent sleep episode (Hanlon, Faraguna, Vyazovskiy, Tononi, & Cirelli,
2009; Huber et al., 2007; Kattler, Dijk, & Borbély, 1994). An increase in
local SWA during sleepmay reflect increased synaptic potentiation elic-
ited by the administered stimulus or task (Tononi & Cirelli, 2014).
The connection between synaptic potentiation and SWA is oneof the
features discussed in the synaptic homeostasis hypothesis (SHY), which
proposes that sleep functions to reestablish synaptic homeostasis after a
period ofwake and learning (Tononi & Cirelli, 2014) (Fig. 2). A key argu-
ment of SHY is that there is an observable net increase and decrease in
synaptic potentiation during wake and sleep, respectively (Tononi &
Cirelli, 2003; Vyazovskiy, Cirelli, Pfister-Genskow, Faraguna, & Tononi,
2008). The SHY suggests that sleep offers an ideal opportunity for the
downregulation or renormalization of synaptic strength owing to the
effective sensory disconnection of the brain from the external environ-
ment (Tononi & Cirelli, 2012). During this process, neuronsmay sample
their inputs without external influence and effectively downregulate
synaptic weights. As argued in the SHY, this process is crucial for main-
taining brain functionality, because a continuous increase in synaptic
strength across neurons cannot be sustained for long. Stronger synapses
consume more space, energy, and cellular resources while ultimately
saturating the capacity for learning and information processing. More-
over, the SHY suggests that the number and strength of synaptic con-
nections are proportional to the amplitude and slope of SWA during
sleep, and that sleep SWAmay be causally involved in synaptic homeo-
stasis. This has been addressed in computer simulations, where higher
synaptic strength, neuronal activity, and synchrony result in increased
SWA, which produces more synaptic depression (Esser, Hill, & Tononi,
2007; Olcese, Esser, & Tononi, 2010). Once synaptic strength is de-
creased, the amount and intensity of SWA decline, providing a self-lim-
iting mechanism. Indeed, numerous experiments have shown that the
markers associated with synaptic potentiation decline during sleep in
a non-linear pattern similar to reduction in SWA during sleep
(Riedner et al., 2007; Tononi & Cirelli, 2020; Vyazovskiy et al., 2009).
These markers include synapse size (Cirelli & Tononi, 2020; de Vivo et
al., 2017), AMPAR expression (Diering et al., 2017; Vyazovskiy et al.,
2008), evoked responses and field excitatory postsynaptic potentials
(Huber et al., 2013; Norimoto et al., 2018; Vyazovskiy et al., 2008). Mo-
lecular mechanisms involved in the down-selection of excitatory
Fig. 2. Sleep restores synaptic and cellular homeostasis. Synaptic potentiation and
synaptogenesis during wakefulness are considerably costly in terms of resources and
space, leading to saturation of neuronal plasticity. To counteract this phenomenon, the
brain undergoes a systematic renormalization of synaptic strength during sleep (Tononi
& Cirelli, 2003; Tononi & Cirelli, 2014), which allows the brain to restore synaptic
plasticity, consolidate learning, and prevent the overflow of metabolic costs associated
with continuous wakefulness. Synaptic potentiation increases as a nonlinear function of
time spent awake, as evidenced by the wake-time–dependent increase in the amplitude
and frequency of miniature excitatory postsynaptic currents (mEPSCs). Synaptic
renormalization during sleep follows homeostatic regulation; the magnitude and
localization of slow-wave electroencephalographic activity (SWA) during nighttime
reflect the intensity and localization of the preceding potentiation. By the end of the day,
certain synapses gain strength according to their activity and new connections are
formed. During sleep, the synapses may be downregulated in proportion to their
strength. In the image, the transition to wake from sleep (baseline) is denoted using
orange eye and arrow. The numerical values on the outer edge represent a cycle of
potentiation in a set of neurons during a sleep-wake cycle.
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tropic glutamate receptors (Diering et al., 2017; Hu et al., 2010), and
GSK3β (Tononi & Cirelli, 2020).
3.3. Association between depression and disturbances in sleep and circa-
dian regulation
Major depression is known to be associated with abnormalities in
circadian regulation and sleep (Benca, 1992; Nutt et al., 2008; Ohayon
& Roth, 2003; Van Cauter & Turek, 1986). Up to 90% of depressed pa-
tients report impaired sleep quality and typically experience prolonged
sleep latency, fragmented sleep, and early morning awakenings
(Riemann et al., 2001; Tsuno et al., 2005). The subjective reports of al-
tered sleep quality are accompanied by electrophysiological findings
of altered sleep architecture affecting both NREM and REM sleep. The
most common finding is a reduction in the amount of SWS (Borbély &
Wirz-Justice, 1982; Tsuno et al., 2005). In addition, depressed patients
display a shorter latency to first REM sleep episode, and the intensity
of REM sleep is increased (Benca et al., 1997); however, these changes
are not specific to affective disorders (Riemann et al., 2020).
Many patients with depression show a diurnal pattern of mood var-
iation, i.e. a lowmood during themorning, which is alleviated through-
out time spent wake towards the evening (Riemann et al., 2020).
Moreover, depression is often modulated by seasonal change, perhaps
due to the changing amount of daylight. Clinical studies indicate a cor-
relation between the degree of desynchronization in circadian rhythms
and the severity of depression (Hasler, Buysse, Kupfer, & Germain,
2010). On the other hand, rhythm disrupting conditions, such as shift
work or jet lag, may worsen depressive mood (Kalmbach, Pillai,
Cheng, Arnedt, & Drake, 2015). In experiments on rodents with the7
central pacemaker rendered either completely aperiodic (Landgraf
et al., 2016), internally desynchronized (forced desynchronization
(Ben-Hamo et al., 2016), or under constant light schedule (Ohta,
Yamazaki, & McMahon, 2005), phases of temperature, locomotion,
and sleep-wake cycles became decoupled from one another. The
decoupling leads to symptoms and changes characteristic for a
depression-like state: anhedonia, sexual dysfunction, behavioral de-
spair, reduction of dendritic complexity in the hippocampus and
mPFC, and altered corticosterone production (Ben-Hamo et al., 2016;
Buijs, Kalsbeek, van der Woude, van Heerikhuize, & Shinn, 1993;
Karatsoreos, Bhagat, Bloss, Morrison, & McEwen, 2011; Phillips,
Savenkova, & Karatsoreos, 2015; Wotus et al., 2013). Indeed, circadian
patterns of gene expression in the human brain have been shown to
be markedly abnormal across six brain areas in MDD (Li et al., 2013).
It could be therefore argued that depressed individuals may have dys-
regulated circadian activity, which could stem from e.g. the central
pacemaker or direct light-dependent regulation of individual brain
areas. For an example of the latter, lateral habenula is directly connected
with SCN – alongside with dopaminergic and serotonergic systems –
and may display both intrinsic oscillations and direct responses to reti-
nal light (Langel et al., 2018; Mendoza, 2017; Riemann et al., 2020).
Effects of conventional antidepressants on sleep have been studied
since the 1960s, however, specific alterations that would explain anti-
depressant actions have not been found. Generally, monoaminergic an-
tidepressants tend to normalize sleep architecture of depressed patients
by reducing the amount of REM sleep and increasing REM latency
(Sandor & Shapiro, 1994). The effects of these drugs on sleep EEG corre-
latewith clinical response and appear to be persistent during long-term
treatment, suggesting that the normalization of sleep architecture
might play a role in the therapeutic action of these drugs (Ehlers,
Havstad, & Kupfer, 1996; Kupfer et al., 1994). Moreover, normalization
of the circadian rhythms commonly emerges alongside with improve-
ment in depressive symptoms (Bunney et al., 2015; Bunney & Bunney,
2012). Perhaps the most fascinating link between sleep, circadian
rhythm, and depression comes from clinical observations with SD. In
healthy controls, SD can increase feelings of dysphoria (Gerner, Post,
Gillin, & Bunney, 1979), while in depressed patients SD can induce re-
markably rapid amelioration of symptoms (Pflug & Tolle, 1971; Wirz-
Justice & Van den Hoofdakker, 1999). Today, SD is used in an inpatient
setting in some countries, with 38,7 % of psychiatric hospitals from Ger-
man speaking countries report having treated patients with SD during
the last 12 months (Winkler et al., 2019). Published studies document
that even up to 50-60% of patients with severe depression respond to
SD, however, the antidepressant effects are highly transient and symp-
toms typically reappear after the next sleep episode (Boland et al.,
2017). Intriguingly, the clinical improvements from SD have been re-
ported to stabilize and better preserve when patients are treated with
lithium (Baxter et al., 1986; Szuba et al., 1994), magnetic stimulation
(Eichhammer et al., 2002), or phase advance (Echizenya, Suda,
Takeshima, Inomata, & Shimizu, 2013; Riemann et al., 1999; Wu et al.,
2009) and bright light therapies (Echizenya et al., 2013; Martiny et al.,
2013; Neumeister et al., 1996). Many unresolved questions remain re-
garding the underlying mechanisms of the antidepressant effects of
SD, but LTP-like synaptic plasticity and transcriptional regulation of cir-
cadian genes have been suggested to be involved (Orozco-Solis et al.,
2017; Wolf et al., 2016). This logically brings us towards the discussion
of how sleep and circadian regulation may be related with the antide-
pressant effects of ketamine and other rapid-acting antidepressants.
4. Rapid-acting antidepressants: shifting the focus towards sleep and
circadian regulation
4.1. Rapid antidepressant effects and sleep homeostasis
How can a single dose of a short-acting drug like ketamine achieve
such rapid, yet long lasting effects? From the perspective of traditional
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get receptors, i.e. blockade of NMDARs, and subsequentmolecular alter-
ations specifically regulated by the ketamine and/or some of its
metabolites. Interestingly, the effects of ketamine are closely connected
to the mechanisms of sleep regulation, as overviewed in Chapter 2,
namely through facilitation of glutamatergic neurotransmission by the
preferential blockade of NMDARs on GABAergic interneurons. This is
thought to lead into disinhibition of pyramidal neurons, and increased
excitation and BDNF release, ultimately resulting in the activation of cel-
lular signaling cascades that facilitate synaptic plasticity and synapto-
genesis. However, approaching this issue from a more neurobiological
perspectivemay offer further insights into the actions rapid-acting anti-
depressants. Here we focus on the effects of ketamine which extend
beyond the acute pharmacological effects, such as neurobiological adap-
tations that emerge in response to ketamine treatment and its with-
drawal. In particular, we review recent studies and hypotheses which
connect the effects of ketamine to physiological mechanisms of sleep
and circadian regulation.
Accumulating data from clinical trials and experts suggests that the
effects of ketamine can be very rapid, with amelioration of depressive
symptoms becoming evident already during the infusion (Kishimoto
et al., 2016; Murrough et al., 2013; Zarate Jr et al., 2006). During this pe-
riod of immediate pharmacological action, ketamine increases gluta-
mate release, energy metabolism, and the secretion of BDNF along
with the activation of multiple molecular pathways that are thought
to contribute to increased protein synthesis and synaptic plasticity. Pa-
tients with robust improvements in depressive symptoms after keta-
mine infusion exhibit increased cortical excitability as measured by
stimulus-evoked somatosensory responses (Nugent et al., 2019). More-
over, several studies have demonstrated increases in gamma power
both acutely and several hours after ketamine treatment in depressed
patients, with some of the studies also showing an association between
gamma power and treatment response (for a thorough review see,
Gilbert & Zarate, 2020). In one study, subjects who had low baseline
gamma power and experienced larger increases in response to keta-
mine showed better antidepressant responses (Nugent, Wills, et al.,
2019). While the dissociative and psychotomimetic effects of ketamine
have also been connected to the acute increase in gamma oscillations,
the sustained and elevated gamma power post-ketamine has been sug-
gested to be a potential biomarker for ketamine-induced synaptic po-
tentiation (Gilbert & Zarate, 2020). These and other studies suggest
that ketamine-induced synaptic potentiation and modulation of net-
work activity may be crucial for the rapid antidepressant effects to de-
velop (Gilbert & Zarate, 2020). This idea is supported by a recent
study in an animal model of chronic stress, where ketamine rapidly re-
stored coordinated activity in cortical neuronal ensembles and normal-
ized behavior (Moda-Sava et al., 2019). Notably, several clinical studies
have reported that the most robust action on depressed mood is often
observed on the following day of the ketamine treatment, i.e., after a
night of sleep (Coyle & Laws, 2015). As previously discussed, arguably
the largest physiological change in the brain takes place from wakeful-
ness to sleep, yet sleep is rarely considered in the study of rapid antide-
pressant effects. Intriguingly, the seminal work of Feinberg and
Campbell (Campbell & Feinberg, 1996; Feinberg & Campbell, 1993)
demonstrated already decades ago that subanesthetic administration
of ketamine or dizocilpine (another NMDAR antagonist) during wake
increases SWA (or delta EEG intensity) during subsequent NREM sleep
in rats. Already in these early studies, the authors pointed out a possible
connection between the effects of ketamine, glutamatergic neurotrans-
mission, and the regulation of sleep homeostasis. The link between the
effects of ketamine and sleep homeostasis is strengthened by a clinical
study, where ketamine increased total sleep time, SWS and REM sleep
in treatment-resistant depressed patients (Duncan et al., 2013). More-
over, the increases in the amount of SWA the night following ketamine
treatment were correlated with mood improvement (Duncan, Sarasso,
et al., 2013). In particular, the group of responders showed significant8
correlations between SWA, slow wave amplitude, and increases in
plasma BDNF (samples collected 230 minutes after the infusion). Since
both increases in sleep SWA and levels of BDNF are functionally related
to synaptic strength, the results support the idea that a net gain of syn-
aptic potentiation takes place during treatment, which results in the in-
creased emergence of SWA during the subsequent sleep period
(Duncan, Sarasso, et al., 2013). In another study, the baseline delta-
sleep ratio (DSR; the ratio of SWAbetween the first twoNREM sleep ep-
isodes) of depressed patients was found to predict the antidepressant
response to ketamine on the day following administration, i.e. after a
night of sleep (Duncan, Selter, Brutsche, Sarasso, & Zarate, 2013).
A low DSR score predicted better treatment response, whereas high
score predicted poor response. As discussed by the authors of the
study, these results suggest that ketamine responders exhibit dysregu-
lated synaptic homeostasis during sleep, which may be positively
affected by the treatment.
The release of BDNF and facilitation of SWAmay be related to corti-
cal excitation induced by subanesthetic ketamine because neuronal uti-
lization during wake by itself has been shown to be sufficient to
upregulate BDNF levels and induce rebound SWA in rodents (Huber,
Tononi, & Cirelli, 2007). Indeed, other rapid-acting treatments of de-
pression affecting cortical excitation during wake, such as SD (Giese et
al., 2014) and electroconvulsive therapy (Rocha et al., 2016), also rap-
idly increase the circulating BDNF levels and SWA during the subse-
quent sleep period in depressed patients (Göder et al., 2016). The
close association between activity-dependent release of BDNF and syn-
aptic homeostasis is further supported by animal studies in which
intracortical BDNF administration increased subsequent sleep SWA in
the injected hemisphere (Faraguna, Vyazovskiy, Nelson, Tononi, &
Cirelli, 2008). In this study, the infusion of either BDNF-blocking anti-
bodies or K252a (a receptor tyrosine kinase inhibitor commonly used
to reduce TrkB activity) led to reduced SWA response. Notably, BDNF
or the blockers did not significantly affect sleep duration, suggesting
that cortical BDNF infusion increases synaptic strength, which contrib-
utes to the generation of SWA (Faraguna et al., 2008). Moreover, other
studies have shown that mice with disrupted activity-dependent Bdnf
promoter IV display a decrease in SWA during NREM sleep (Hill et al.,
2016). These results are also supported by human studies in which sub-
jects with the Val66Met BDNF polymorphism – which impairs activity-
dependent BDNF secretion – show lower SWS intensity after SD than
those with the Val66Val BDNF polymorphism (Bachmann et al., 2012).
It is well established that BDNF is a keymediator of synaptic plastic-
ity and strength in the adult brain (Park & Poo, 2013), and SWA may
represent the synaptic strength of cortical circuits. As proposed by the
SHY, increased synaptic potentiation is observed as increased SWAdur-
ing subsequent NREM sleep, when the renormalization of synaptic
strength occurs. In this context, it remains possible that ketamine, and
several other excitatory treatments, are capable of rapidly engaging cor-
tical microcircuits, thus increasing their activity and synaptic strength.
This increase in synaptic strength is reflected in the increased amount
of SWA observed during subsequent sleep period. The SHY proposes
that the global renormalization of synaptic strength occurs during
SWS, whereas synapses that were particularly active and potentiated
during preceding wakefulness may be protected, to a certain extent,
from this process. The underlying mechanisms remain speculative at
this time, but the proposed framework may be highly relevant for un-
derstanding learning and memory consolidation and exploring how
rapid antidepressant effects emerge and, especially, sustain over time.
In the recent years, several new hypotheses have approached
rapid and sustained antidepressant effects through the function of
sleep. A recently formulated hypothesis of encoding, consolidation and
renormalization in depression (ENCORE-D) views rapid antidepressant
effects by separating the rapid onset and realization of the sustained ac-
tion into three consecutive phases (Rantamäki & Kohtala, 2020) (Fig. 3).
The first phase, encoding, constitutes events that occur under the acute
pharmacological effects of a drug (i.e. engagement of target receptors).
Fig. 3. Chronotherapeutic features are integral components of rapid-acting antidepressants. A. Subanesthetic ketamine transiently evokes glutamatergic neurotransmission in the cortex
during peak pharmacological effects, for example, through inhibition of N-methyl-D-aspartate receptors (NMDAR) on GABAergic interneurons and facilitation of α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated neurotransmission. Excitatory neurotransmission is also facilitated during sleep deprivation. Increased excitation results in
synaptic potentiation, which is then reflected in more prominent slow wave activity (SWA) during the subsequent sleep episode. According to the encoding, consolidation and
renormalization in depression (ENCORE-D) hypothesis (Rantamäki & Kohtala, 2020), this phenomenon is important for sustaining the antidepressant effects of ketamine. B. A
hypothesis by Wolf et al. (2016) suggests that depression (dashed line) is characterized by a deficiency in synaptic plasticity and an inability of synapses to reach an optimal zone of
potentiation where long-term potentiation can be induced. Sleep deprivation and, possibly, ketamine can therefore be utilized to increase cortical excitability and synaptic
potentiation, compensating for the impaired associative plasticity of the depressed brain. C. Molecular mechanisms associated with the therapeutic effects of rapid-acting
antidepressants are also principal components of circadian clockwork and intrinsic brain excitability. Various pharmacological and non-pharmacological treatments of depression
produce similar changes in the expression of proteins associated with process S (synaptic potentiation), and/or process C (timing and amplitude of circadian clock output). TrkB,
tropomyosin-related kinase B; MAPK, mitogen-activated protein kinase (also known as extracellular signal-regulated kinase or ERK); mTor, mammalian target of rapamycin; GSK3β,
glycogen synthase kinase β; CREB, cAMP response element-binding protein.
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cortical neurocircuits – by facilitating glutamatergic activity – alters
their computational properties and patterns of connectivity. This rap-
idly switches network functionality and normalizes depressogenic cog-
nitive processes while facilitating the encoding of healthy network
activity and accrual of synaptic strength – processes thatmay be dysreg-
ulated in, for example, chronic depressive rumination – for the remain-
der of the day. Hypothetically, the gradual cessation of the acute
pharmacological effects triggers a second phase that involves the ho-
meostatic emergence of SWA in activated neurocircuits while awake,
which coincides with molecular signaling events and synthesis of pro-
teins involved in the consolidation of synaptic plasticity. Such phenom-
enon is also observed in experiments with nitrous oxide (“laughing
gas”), another NMDAR antagonist and a putative rapid-acting antide-
pressant (Nagele et al., 2015), which evokes cortical SWA specifically
upon drug withdrawal accompanied by enhanced TrkB, GSK3β and
p70S6K (an effector of mTOR) signaling (Kohtala et al., 2019). More-
over, subanesthetic ketamine and various other treatments that possess
rapid antidepressant potential, such as ECT, flurothyl, and theta burst
stimulation, increase SWA after the acute pharmacological (or physio-
logical) effects have dissipated (Assenza, Pellegrino, Tombini, Di Pino,
& Di Lazzaro, 2015; Kohtala, Theilmann, Rosenholm, Penna, et al.,9
2019; Sackeim et al., 1996). Finally, the third phase occurs during subse-
quent SWS, a period during which, according to the SHY, cortical
neurocircuits undergo synaptic renormalization (Tononi & Cirelli,
2014), challenged by increased synaptic strength and synaptogenesis
(Li et al., 2010). ENCORE-D suggests that this phenomenon gives rise
to more persistent changes in circuit activity, by allowing ketamine-in-
duced synaptic changes to bemaintained, whereas the processes attrib-
uted to the maintenance of depressive cognitive processing may be
downregulated (Rantamäki & Kohtala, 2020). These effects culminate
the following day, when themost robust antidepressant effects become
evident along with normalized patterns of global functional conn-
ectivity (Abdallah et al., 2017). Most importantly, ENCORE-D suggests
that the core of ketamine’s effects lies in its ability to transiently alter
neuronal activity in cortical circuits, which recruits the activity of fun-
damental homeostatic processes during SWS, ultimately altering the
patterns of neural activity and flow of implicit cognitive processes ben-
eficial formaintaining thought patterns free of depression (Rantamäki&
Kohtala, 2020). Furthermore, the principles of the hypothesis can be
applied to examine both the pathophysiology leading to depression
(i.e. aberrant accrual and maintenance of synaptic strength in
depressogenic networks) and the relapse of depressive symptoms
over time (i.e. several wake-sleep cycles). Although ENCORE-D remains
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tively proposes a novel framework for examining rapid and sustained
antidepressant effects from the perspective of sleep.
Another hypothesis, the synaptic plasticity model of SD as a treat-
ment of depression, similarly focuses on synaptic homeostasis and
sleep/wake-dependent shifts in synaptic plasticity particularly influ-
enced by SD (Wolf et al., 2016). In this hypothesis, depression is charac-
terized by deficient synaptic plasticity and the inability of synapses to
reach an optimal zone for LTP inducibility. Studies demonstrating di-
minished hippocampal LTP inducibility in animal models of depression
(Alfarez et al., 2003) and a decrease in LTP-like cortical plasticity in pa-
tients suffering from depression (Normann et al., 2007; Player et al.,
2013) provide support for the general idea. In particular, the hypothesis
proposes that SD extends the period when cortical neurons may in-
crease their synaptic strength or excitability, which compensates for
the attenuated associative plasticity in depression and leads to the ame-
lioration of depressive symptoms. Notably, rodent studies have shown
that wakefulness increases the slope and amplitude of evoked cortical
responses, whereas a decrease is observed after sleep (Vyazovskiy et
al., 2008). Moreover, the levels of extrasynaptic glutamate (Dash,
Douglas, Vyazovskiy, Cirelli, & Tononi, 2009), frequency and amplitude
of miniature excitatory postsynaptic currents, and mean firing rate
and synchronization of cortical neurons increase after prolonged wake-
fulness (Liu, Faraguna, Cirelli, Tononi, &Gao, 2010). Human studies have
also demonstrated an increase in cortical excitability during wakeful-
ness (Huber et al., 2013). The notion that depressive symptoms are as-
sociated with dysregulated synaptic strength is supported by indirect
evidence from a study where cortical excitability was measured as a
proxy of synaptic strength in patients with bipolar depression (Canali
et al., 2014). The study demonstrated that changes in cortical excitabil-
ity parallel and predict antidepressant responses to SD and light ther-
apy. Together, these and other findings provide support for increases
in cortical synaptic strength in association with time spent awake. In
its current form, the model byWolf et al. (2016) provides an intriguing
perspective on how SDmay act throughmodulating themechanisms of
synaptic plasticity and sleep to ultimately influence depressive symp-
toms. This framework could also potentially be applied to examine ex-
citatory drugs such as ketamine, which also affects cortical excitability
(Rantamäki & Kohtala, 2020).
4.2. Antidepressant effects of ketamine and circadian regulation
Emerging views highlight the role of circadian dysregulation in the
pathophysiology of depression and regulation of mood (see Chapter
3.3.). Indeed, traditional antidepressantsmay influence circadianmech-
anisms and modulate sleep structure. It appears reasonable that the ef-
fects of ketamine may also recruit circadian mechanisms, which
participate in the rapid and sustained recovery of depressive symptoms.
Although the effects of ketamine on circadian regulation are not fully
elucidated, several studies suggest that many of the molecular targets
regulated by ketamine are also closely associated with modulation of
circadian systems.
Preclinical studies indicate that both SD and ketamine influence the
function of the circadianmolecular components, leading to altered clock
gene transcriptional output levels (Bellet, Vawter, Bunney, Bunney, &
Sassone-Corsi, 2011; Bunney et al., 2015; Orozco-Solis et al., 2017;
Wisor et al., 2008) (Fig. 3), but the precise underlying mechanisms
can be only speculated at this point. The intracellular pathways leading
from entraining cue-induced neuronal activation to gene expression are
originally initiated by neuronal activity triggering Ca2+-regulated pro-
tein kinases (Golombek & Rosenstein, 2010; Meijer & Schwartz, 2003).
The Ca2+ signaling is mobilized by various mechanisms including
NMDAR activation, voltage-gated calcium channel opening, release
from intracellular storage, and G protein-coupled receptor-mediated
signaling (West et al., 2001). A recent study shows that ketamine trig-
gers a gradual emergence of synaptic calcium transients in pyramidal10neurons within the PFC (Ali et al., 2020). Experimental evidence sug-
gests that, downstream of Ca2+ influx, ERK1/2, GSK3β, protein kinases
A and G (PKA and PKG), and Ca2+-calmodulin-dependent protein ki-
nases play a key role in the modulation of clock phase shifts in rodent
SCN (Alessandro, Golombek, & Chiesa, 2019; Iitaka, Miyazaki, Akaike,
& Ishida, 2005). Eventually, various excitatory stimuli that are sufficient
to synchronize the circadian clock lead to the phosphorylation of CREB
at the transcriptional activation site Ser133, initiating expression of
IEGs and clock-controlled genes (Ginty et al., 1993; Hastings et al.,
1997; Lee et al., 2010; Lonze & Ginty, 2002). Thus, the CREB pathway
serves as a crucial point of convergence for various cues of photic and
non-photic origin in the synchronization of circadian rhythmicity. Nota-
bly, the acute pharmacological effects of ketamine also converge on the
same pathways, resulting in the regulation of core components of the
mammalian circadian clock (Beurel et al., 2011; Beurel, Grieco,
Amadei, Downey, & Jope, 2016; Kohtala, Theilmann, Rosenholm,
Müller, et al., 2019; Ma et al., 2017; Réus et al., 2016; Wang et al.,
2020; Wray, Schappi, Singh, Senese, & Rasenick, 2019); INFOBOX). Cer-
tain aspects of the potential impact of ketamine on circadian rhythms
can also be examined through its effects on energy expenditure and be-
havior (increase in locomotor activity; see, e.g., Campbell & Feinberg,
1996; Feinberg & Campbell, 1993), both strong non-photic entraining
cues for circadian rhythm. Indeed, a common feature of non-photic
stimuli is their ability to arouse and increase physical activity (and
thereby energy consumption) (Hastings, Duffield, Smith, Maywood, &
Ebling, 1998; Mrosovsky, 1996). Notably, the effects of arousal are
most pronounced at the endof the inactive phase (Hastings et al., 1998).
At this stage, it remains unclear at what level subanesthetic keta-
minemay affect circadian regulation, andwhether these effects areme-
diated through a global increase in cortical activity or more specific
effects on individual brain areas and circuits. A model by Duncan et al.
(2017) suggests that the effects of ketamine may be explained through
alterations in both the homeostatic (S) and circadian (C) components of
sleep. Specifically, this hypothesis proposes that diminished interac-
tions between these mechanisms promote depressed mood. Treatment
with ketamine increases plasticity, SWS, and sleep qualitywhile altering
circadian timing and output. By increasing the circadian amplitude and
shifting its phase, ketamine restores the circadian misalignments pres-
ent in depressed patients. Indeed, human studies have reported an asso-
ciation between the antidepressant effects of ketamine and circadian
timekeeping (Duncan et al., 2017; Duncan et al., 2018). Previous studies
have also reported a correlation between ketamine-induced changes in
BDNF levels, SWS, sleep quality, and concomitant mood changes in
treatment-resistant depression (Duncan, Sarasso, et al., 2013; Duncan
& Zarate, 2013). Duncan et al. (2017) discuss various potential effects
of ketamine’s on circadian timekeeping. For example, ketaminemay af-
fect the timekeeping of the central clock or alter its synchronization to
external light cycles. Its effects may also stem from its impact on the ex-
pression of non-central clock genes. Additionally, it should be noted that
processes S and C complement each other (Deboer, 2018), and the ef-
fects of ketamine cannot be isolated to either individually. Sufficient
neuronal activity alters circadian output by entraining the circadian
clock, and conversely, the threshold for synaptic potentiation occurring
in response to neuronal activity is lower during proper circadian time.
The lateral habenula (LHb) is one of the brain areas that are con-
nected with the SCN and could be potential candidates for circadian ef-
fects induced by ketamine. The LHb appears to function as an individual
circadian oscillator in the central nervous system (Mendoza, 2017). Hy-
peractivity of the LHb has been recently associated with the pathophys-
iology of depression (Aizawa, Cui, Tanaka, & Okamoto, 2013; Hu, Cui, &
Yang, 2020; Lecca,Meye, &Mameli, 2014; Li et al., 2011). In particular, it
exhibits inhibitory control over connecting dopaminergic, noradrener-
gic, and serotonergic areas. Increased activity of the neurons in the
LHb may, therefore, promote stronger inhibitory control over these
areas and have a negative influence on mood regulation. Notably, a re-
cent rodent study demonstrated that depressive-like animals show
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tamine (Yang et al., 2018). In line with these results, the downregula-
tion of LHb reduces default mode network connectivity in rats
(ClemmvonHohenberg et al., 2018). Defaultmodenetwork hyperactiv-
ity is a common feature replicated in several neuroimaging studies of
depressed patients (Zhou et al., 2020).
In addition to the effects of ketamine on circadian mechanisms,
circadian rhythms and the time of drug administration may also di-
rectly affect the pharmacology of ketamine. The ability of ketamine
to regulate specific molecular, cellular, and functional targets in-
volved in antidepressant effects may differ depending on the
phase of the circadian cycle. Indeed, the time of drug administration
has significant effects on the efficacy of various drugs; however, the
impact of the timing of drug delivery has generally received very lit-
tle attention in medicine (Ruben, Smith, FitzGerald, & Hogenesch,
2019). Circadian oscillations in the physiological functions of the
body result in considerable diurnal variations in the expression of
drug targets and drug metabolizing enzymes (Levi & Schibler,
2007). The brain is no exception; the synaptic function undergoes
a distinct circadian variation (Nakatsuka & Natsume, 2014;
Pennartz, Hamstra, & Geurtsen, 2001; Wang et al., 2012). A recent
study demonstrated circadian rhythmicity in approximately 70 %
of synaptic transcripts from mouse forebrain, highlighting the role
of neuronal circadian clocks in the anticipation of environmental cy-
cles (Noya et al., 2019). The transcriptional peaks of genes associ-
ated with synaptic transmission were observed before the
transition to wakefulness, whereas those of genes associated with
intracellular signaling, translation, cell morphology, and metabo-
lism, were observed before the transition to sleep. The synaptic
transcriptional machinery works resiliently according to the circa-
dian clock rhythm. When subjected to SD, the circadian oscillations
in mRNA expression remain unaltered or are reduced only slightly.
In contrast, the circadian rhythms of protein abundance and phos-
phorylation status are considerably more dependent on the quality
and duration of the preceding wake or sleep period (Brüning et al.,
2019; Noya et al., 2019). Thus, gene transcription is heavily con-
trolled by circadian components, whereas the post-translational
modifications enable rapid changes in the system on the basis of en-
vironmental changes. The availability of central receptor targets of
ketamine, such as NMDAR and AMPAR subunit mRNAs, also un-
dergoes circadian periodicity within the SCN (Chambille, 1999;
Ishida, Matsui, Mitsui, & Mishina, 1994). This fluctuation may par-
tially explain the circadian variations in the hypnotic efficacy of ke-
tamine in rodents (Rebuelto, Ambros, Montoya, & Bonafine, 2002;
Rebuelto, Ambros, Waxman, & Montoya, 2004; Sato et al., 2004).
Moreover, total protein expression and phosphorylation levels of
the molecular determinants of synaptic plasticity, such as calcium-
calmodulin dependent protein kinase II, GSK3β, and glutamate re-
ceptor 1, are differentially regulated during sleep and wake in the
rat brain (Vyazovskiy et al., 2008). GSK3β (Besing et al., 2017) and
ERK1/2 activity also undergo circadian regulation (Coogan &
Piggins, 2004; Obrietan, Impey, & Storm, 1998).
Finally, basic pharmacokinetic properties of ketamine may also be
affected by circadian fluctuations and the wake-sleep cycle. The distri-
bution of drugs affecting the central nervous system is generally influ-
enced by the diurnal variations in the blood-brain barrier permeability
(Cuddapah, Zhang, & Sehgal, 2019). Notably, sleep loss dramatically in-
creases blood-brain barrier permeability (He et al., 2014). Considering
that ketamine undergoes hepatic metabolism (Mössner, Schmitz,
Theurillat, Thormann, &Mevissen, 2011), a process susceptible to circa-
dian rhythmicity, and that its HNKmetabolites potentially have antide-
pressant effects, it is even more likely that the therapeutic effects of
ketamine are affected by the time of administration. For example,
more HNK is produced when ketamine is administered during the ac-
tive phase of the animal (Martinez-Lozano Sinues, Kohler, Brown,
Zenobi, & Dallmann, 2017).114.3. Unforeseen consequences
As outlined in the previous chapters, many of the mechanisms in-
volved in the antidepressant effects of ketamine are also interconnected
with physiological circadian rhythmicity and/or the sleep-wake cycle.
These intrinsic oscillations occur at all levels ranging from molecular
to cellular, and on a scale ranging from electrophysiological to ultra-
structural – ultimately also modulating cognition, mood, and behavior.
They span a wide range of different states and associated phenotypes,
from the active wakefulness of a well-rested brain to the heavily fa-
tigued and dysfunctional brain at the end of a long period of wakeful-
ness. Furthermore, the brain does not cease to be inactive once asleep
but instead cycles through periods of NREM and REM sleep in addition
to complex patterns of coinciding electrical activities. While the precise
functions of these patterns of activity remain amatter of intense debate,
it is clear that sleep has a fundamental role in the maintenance of brain
health, plasticity, and healthy cognition.
An increase in the cortical firing rates and synchrony (Vyazovskiy et
al., 2009) and slope and amplitude of evoked cortical responses occur
during wakefulness (Vyazovskiy et al., 2008). Moreover, the mean ex-
pression levels of synaptic AMPARs and their phosphorylation levels,
which indicate synaptic potentiation, are higher during wakefulness
than during sleep in both rat cortex and hippocampus (Vyazovskiy et
al., 2008), and in themouse forebrain (Diering et al., 2017). Conversely,
the frequency and amplitude of miniature excitatory postsynaptic
currents (Liu et al., 2010), spine density, and number of AMPARs
(Diering et al., 2017; Maret, Faraguna, Nelson, Cirelli, & Tononi, 2011;
Vyazovskiy et al., 2008; Yang & Gan, 2012) decrease during sleep. Re-
cent ultrastructural studies of the mouse motor and sensory cortices
have shown that the axon-spine interface is decreased – indicative of
decreased synaptic strength (Nishiyama & Yasuda, 2015) – after sleep
than after the wakeful period (Cirelli & Tononi, 2020; de Vivo et al.,
2017). In addition, in adolescent mice, waking time is associated with
an increase in synapse density and axon-spine interface in the hippo-
campus (Spano et al., 2019). Taken together, these and other findings
highlight the strong synaptic regulation that occurs during wake and
sleep. Because the antidepressant-like effects of ketamine seem to re-
quire AMPARs and are associated with changes in synaptic proteins
and increased synaptogenesis, the possibility exists that unforeseen
consequences emerge from the interaction of ketamine with the ho-
meostatic mechanisms associated with wakefulness and sleep.
The effects of ketaminemay also bemodulated by homeostatic pres-
sure and/or circadian time at the time of administration, as has been
previously suggested by animal studies investigating the anesthetic ef-
fects of ketamine (Giedt, Lakin, & Winters, 1978; Rebuelto et al.,
2002). In this context, the intrinsic regulation of cortical excitability
may be particularly important because it influences the basal function-
ality of a given circuit and the circuits response to an external stimulus.
Indeed, it is now known that prolongedwakefulness leads to changes in
cortical excitability, which is not only important for normal brain func-
tion and cognition butmay also influence the pharmacological effects of
drugs targeting the nervous system. For example, treatments given
early in the morning may produce different outcomes than those
given late in the evening, because cortical excitability is regulated by cir-
cadian rhythmicity (Ly et al., 2016) as well as wake and sleep (Kuhn et
al., 2016). Thus, all therapeutics that elicit their primary effects through
the regulation of, for example, excitatory neurotransmission may
be modulated according to the time of administration and the basal
state of the brain. Additionally, an excitatory stimulus may lead to dif-
ferent circadian responses depending on the time of day it is experi-
enced (De Coursey, 1960; Khalsa, Jewett, Cajochen, & Czeisler, 2003;
Pittendrigh, 1988). Stronger cues either advance or postpone the circa-
dian rhythm, depending on whether they are experienced in themorn-
ing or evening, respectively. Timing may also contribute to many of the
studies addressing antidepressant effects using functional imaging
methods: a recent study suggested an association between time of day
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connectivity in humans (Orban, Kong, Li, Chee, & Yeo, 2020). In addition,
brain glucose utilizationmeasured using positron emission tomography
undergoes significant diurnal variation, which is altered in depressed
patients (Germain et al., 2007). Remarkably, the effect of experiment
timing in subanesthetic ketamine or other rapid acting treatments of
depression has not been clinically addressed; however, such studies
have been planned (Zhuo et al., 2019).
A significant impact of treatment timing would indicate that
many of the studies on the effects of ketamine in animal models,
on multiple levels of inquiry, are only representative of the underly-
ing basal conditions. Although sleep and circadian regulation likely
serve similar functions in all animals, several features of the sleep-
wake cycle, such as sleep architecture and circadian rhythms, are
significantly different in humans and widely used experimental ani-
mals. Humans are diurnal and commonly sleep in one consolidated
period during the dark phase. However, rodents undergo a polypha-
sic, segmented sleep rhythm and sleep in multiple shorter bouts
throughout the 24 hours (Le Bon et al., 2007). Most importantly, in
contrast to humans, most laboratory rodents are nocturnal and
sleep predominantly during the light phase. Two-thirds of seg-
mented sleep cycles occur during the light hours (i.e. the inactive pe-
riod). As the remaining third of the time spent asleep occurs during
the dark phase, the distinction between day and night is not as ex-
plicit in rodents as in humans. However, in preclinical research, ani-
mal handling and treatments are generally conducted during
standard laboratory hours during the day, which corresponds to
the inactive phase of nocturnal rodents and when the animals ex-
hibit high sleep pressure (Alitalo, Saarreharju, Zarate, Kohtala, &
Rantamaki, 2020). To date, this discrepancy has received very little
attention in the field despite an abundance of evidence suggesting
the involvement of sleep and circadian mechanisms.
It is important to acknowledge the effect of an activating stimulus
during a period when the animals prefer to sleep. Indeed, in rodents,
lower doses of ketamine are commonly found to stimulate loco-
motor activity – a strong non-photic entrainment cue (Chang et al.,
2019; Usun, Eybrard, Meyer, & Louilot, 2013; Yamamoto et al.,
2016). Moreover, in rats, subanesthetic doses of ketamine acutely
inhibit REM sleep, increase high-frequency gamma oscillations
(52–100 Hz) and alter the dynamics of theta-gamma phase-am-
plitude coupling (Ahnaou, Huysmans, Biermans, Manyakov, &
Drinkenburg, 2017). However, the interpretation of studies involv-
ing certain effects of ketamine is complicated owing to the variance
in stimulatory responses according to sex and age of the animals
(Crawford et al., 2020). Nevertheless, these studies imply that
subanesthetic doses of ketamine are likely to disrupt physiological
patterns of sleep, especially when delivered during the inactive pe-
riod. Other excitatory stimuli, ranging from bright light (Benloucif,
Masana, & Dubocovich, 1997) to electroconvulsive shocks (Quigg,
Straume, Smith, Menaker, & Bertram, 2001), induce circadian
phase shifts. In both rodents and humans, a light impulse experi-
enced in early inactive period leads to a delay in circadian phase
and therefore increased sleep latency. Considering that light-in-
duced shifts in circadian phase are mediated by glutamatergic neu-
rotransmission (Ebling, 1996; Mintz, Marvel, Gillespie, Price, &
Albers, 1999), it is possible to speculate the nature of the effects of
subanesthetic ketamine that lead to a glutamate burst. Unfortu-
nately, there is a lack of research on the consequences of such dis-
ruption in the context of ketamine for the interpretation of
behavioral or molecular studies. Nevertheless, it is well known that
SD has antidepressant-like effects – similar to traditional antidepres-
sants – in behavioral assays in animals, such as the forced swim test.
In one study, rats subjected to total sleep deprivation for 24 hours
demonstrated increased swimming behavior immediately after-
wards as well as 48 hours later (Lopez-Rodriguez, Kim, & Poland,
2004). Similarly, REM sleep deprivation decreases immobility12(Hawkins et al., 1980; Van Luijtelaar & Coenen, 1985). In light of
the activity-promoting effects of ketamine and its ability to acutely
suppress REM sleep and modulate circadian rhythms, it remains
plausible that ketamine administered during the inactive phase has
complex interactions with these systems, often remaining unac-
counted for in basic research. Indeed, the need for an improved un-
derstanding of this topic is exemplified in recent research
regarding the difference in the effects of rapastinel and ketamine
on animal behavior and electrophysiology (Banerjee, Donello, Hare,
& Duman, 2020); ketamine produces increased locomotor activity
and a significant increase in sleep latency, because the treatments
were administered early in the light phase. According to EEG activ-
ity, the animals still exhibit a high amount of SWS during their nor-
mal activity period, reflective of residual sleep pressure from the
earlier sleep deprivation. Banerjee et al. (2020) discuss this phenom-
enon to support that rapastinel has a more beneficial side-effect pro-
file than ketamine; however, they do not consider the effect of time
of drug administration on their results. In this case, and perhaps
other cases, the effects attributed solely to ketamine could therefore
be masked – to a certain extent – by those of sleep disruption or dep-
rivation, likely constituting a major confounding factor in studies in-
vestigating the effects of ketamine on depressive-like behavior,
associated molecular pathways, and electrophysiological changes.
5. Closing remarks
The main purpose of this review is to call attention to chronobiolog-
ical processes, especially sleep, in themechanisms of action of ketamine
and other treatments capable of producing rapid and sustained antide-
pressant effects. Combining the various known effects of ketaminewith
the regulation of sleep and wake may be instrumental in depicting the
fundamental underpinnings of its therapeutic effects. Several recent hy-
potheses of rapid antidepressant action have emerged, where sleep or
circadian rhythms are considered to play a crucial role. These new per-
spectives warrant further interest and examination from researchers
from various backgrounds, such as pharmacologists,molecular neurobi-
ologists, and sleep researchers. Indeed, only time – and meticulous sci-
entific research – will tell how sleep and circadian regulation are
associated with the antidepressant effects of ketamine and whether it
is one of the last pieces of the puzzle necessary to gain a more compre-
hensive understanding of ketamine’s actions in the brain.
Authorship contributions
O.A., S.R., M.R., S.K., and T.R. wrote or contributed to the writing of
the manuscript. O.A. prepared figures and other artwork.
Declaration of Competing Interest
T.R. and S.K. are listed as co-inventors on a patent application
wherein in new tools enabling the development of rapid-acting antide-
pressants and the efficacy monitors thereof are disclosed based on the
basic principles of ENCORE-D. T.R. and S.K. have assigned their patent
rights to the University of Helsinki but will share a percentage of any
royalties thatmay be received by theUniversity of Helsinki. All other au-
thors declare that there are no conflicts of interest.
Acknowledgements
We thank Dr. Tarja Stenberg for her valuable comments on theman-
uscript. This work has been supported by the Academy of Finland (T.R.,
Grants 276333, 305195, 312664; S.R., Grant 322906), the Orion Re-
search Foundation (S.K.), the Finnish Pharmaceutical Society (S.K., M.
R.), and the Doctoral Programme In Drug Research, University of Hel-
sinki (O.A.). The funding sources were not involved in writing or deci-
sion to submit the work.
S. Kohtala, O. Alitalo, M. Rosenholm et al. Pharmacology & Therapeutics 221 (2021) 107741References
Aan Het Rot, M., Zarate, C. A., Charney, D. S., & Mathew, S. J. (2012). Ketamine for depres-
sion: where do we go from here? Biological Psychiatry 72, 537–547.
Abdallah, C. G., Averill, L. A., Collins, K. A., Geha, P., Schwartz, J., Averill, C., et al. (2017).
Ketamine treatment and global brain connectivity in major depression.
Neuropsychopharmacology 42, 1210–1219.
Abdallah, C. G., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., et al.
(2020). Modulation of the antidepressant effects of ketamine by the mTORC1 inhib-
itor rapamycin. Neuropsychopharmacology 45, 990–997.
Abdallah, C. G., De Feyter, H. M., Averill, L. A., Jiang, L., Averill, C. L., Chowdhury, G. M. I.,
et al. (2018). The effects of ketamine on prefrontal glutamate neurotransmission in
healthy and depressed subjects. Neuropsychopharmacology 43, 2154–2160.
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018). The neurobiology of de-
pression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or ac-
tivation? Pharmacology and Therapeutics 190, 148–158.
Abe, M., Herzog, E. D., Yamazaki, S., Straume, M., Tei, H., Sakaki, Y., et al. (2002). Circadian
rhythms in isolated brain regions. The Journal of Neuroscience 22, 350–356.
Abrahamson, E. E., & Moore, R. Y. (2001). Suprachiasmatic nucleus in the mouse: retinal
innervation, intrinsic organization and efferent projections. Brain Research 916,
172–191.
Achermann, P., Dijk, D. -J., Brunner, D. P., & Borbély, A. A. (1993). A model of human sleep
homeostasis based on EEG slow-wave activity: Quantitative comparison of data and
simulations. Brain Research Bulletin 31, 97–113.
Ahnaou, A., Huysmans, H., Biermans, R., Manyakov, N. V., & Drinkenburg, W. H. I. M.
(2017). Ketamine: differential neurophysiological dynamics in functional networks
in the rat brain. Translational Psychiatry 7, e1237.
Aizawa, H., Cui, W., Tanaka, K., & Okamoto, H. (2013). Hyperactivation of the habenula as
a link between depression and sleep disturbance. Frontiers in Human Neuroscience 7,
826.
Alessandro, M. S., Golombek, D. A., & Chiesa, J. J. (2019). Protein kinases in the photic sig-
naling of the mammalian circadian clock. The Yale Journal of Biology and Medicine 92,
241–250.
Alfarez, D. N., Joëls, M., & Krugers, H. J. (2003). Chronic unpredictable stress impairs long-
term potentiation in rat hippocampal CA1 area and dentate gyrus in vitro. European
Journal of Neuroscience 17, 1928–1934.
Ali, F., Gerhard, D. M., Sweasy, K., Pothula, S., Pittenger, C., Duman, R. S., & Kwan, A. C.
(2020). Ketamine disinhibits dendrites and enhances calcium signals in prefrontal
dendritic spines. Nature Communications 11, 72.
Alitalo, O., Saarreharju, R., Zarate, C. A., Kohtala, S., & Rantamaki, T. (2020). A wake-up call
- Revealing the oversight of sleep physiology and related translational discrepancies
in studies of rapid-acting antidepressants. MedRxiv. https://doi.org/10.1101/2020.09.
29.20204008.
Anafi, R. C., Kayser, M. S., & Raizen, D. M. (2019). Exploring phylogeny to find the function
of sleep. Nature Reviews. Neuroscience 20, 109–116.
Artiushin, G., & Sehgal, A. (2020). The glial perspective on sleep and circadian rhythms.
Annual Review of Neuroscience 43, 119–140.
Assenza, G., Pellegrino, G., Tombini, M., Di Pino, G., & Di Lazzaro, V. (2015). Wakefulness
delta waves increase after cortical plasticity induction. Clinical Neurophysiology 126,
1221–1227.
Astiz, M., Heyde, I., & Oster, H. (2019). Mechanisms of communication in the mammalian
circadian timing system. International Journal of Molecular Sciences 20, 343.
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P., et al. (2011). NMDA re-
ceptor blockade at rest triggers rapid behavioural antidepressant responses. Nature
475, 91–95.
Autry, A. E., & Monteggia, L. M. (2012). Brain-derived neurotrophic factor and neuropsy-
chiatric disorders. Pharmacological Reviews 64, 238–258.
Bachmann, V., Klein, C., Bodenmann, S., Schäfer, N., Berger, W., Brugger, P., & Landolt, H. -
P. (2012). The BDNF Val66Met polymorphism modulates sleep intensity: EEG fre-
quency- and state-specificity. Sleep 35, 335–344.
Baltaci, S. B., Mogulkoc, R., & Baltaci, A. K. (2019). Molecular mechanisms of early and late
LTP. Neurochemical Research 44, 281–296.
Banerjee, P., Donello, J. E., Hare, B., & Duman, R. S. (2020). Rapastinel, an NMDAR positive
modulator, produces distinct behavioral, sleep, and EEG profiles compared with keta-
mine. Behavioural Brain Research 391, 112706.
Bass, J., & Takahashi, J. S. (2010). Circadian integration of metabolism and energetics.
Science 330, 1349–1354.
Baxter, L. R., Liston, E. H., Schwartz, J. M., Altshuler, L. L., Wilkins, J. N., Richeimer, S., &
Guze, B. H. (1986). Prolongation of the antidepressant response to partial sleep dep-
rivation by lithium. Psychiatry Research 19, 17–23.
Bellesi, M., Bushey, D., Chini, M., Tononi, G., & Cirelli, C. (2016). Contribution of sleep to
the repair of neuronal DNA double-strand breaks: Evidence from flies and mice.
Scientific Reports 6, 36804.
Bellet, M. M., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2011). Ke-
tamine influences CLOCK:BMAL1 function leading to altered circadian gene expres-
sion. PloS One 6, 1–7.
Benca, R. M. (1992). Sleep and psychiatric disorders: A meta-analysis. Archives of General
Psychiatry 49, 651.
Benca, R. M., Okawa, M., Uchiyama, M., Ozaki, S., Nakajima, T., Shibui, K., & Obermeyer, W.
H. (1997). Sleep and mood disorders. Sleep Medicine Reviews 1, 45–56.
Ben-Hamo, M., Larson, T. A., Duge, L. S., Sikkema, C., Wilkinson, C.W., de la Iglesia, H. O., &
González, M. M. C. (2016). Circadian forced desynchrony of the master clock leads to
phenotypic manifestation of depression in rats. ENeuro 3 (ENEURO.0237-16.2016).
Benington, J. H., & Heller, H. C. (1995). Restoration of brain energy metabolism as the
function of sleep. Progress in Neurobiology 45, 347–360.13Benloucif, S., Masana, M. I., & Dubocovich, M. L. (1997). Light-induced phase shifts of cir-
cadian activity rhythms and immediate early gene expression in the suprachiasmatic
nucleus are attenuated in old C3H/HeN mice. Brain Research 747, 34–42.
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., &
Krystal, J. H. (2000). Antidepressant effects of ketamine in depressed patients.
Biological Psychiatry 47, 351–354.
Besing, R. C., Rogers, C. O., Paul, J. R., Hablitz, L. M., Johnson, R. L., McMahon, L. L., &
Gamble, K. L. (2017). GSK3 activity regulates rhythms in hippocampal clock gene ex-
pression and synaptic plasticity. Hippocampus 27, 890–898.
Beurel, E., Grieco, S. F., Amadei, C., Downey, K., & Jope, R. S. (2016). Ketamine-induced in-
hibition of glycogen synthase kinase-3 contributes to the augmentation of α-amino-
3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor signaling. Bipolar
Disorders 18, 473–480.
Beurel, E., Song, L., & Jope, R. (2011). Inhibition of glycogen synthase kinase-3 is necessary
for the rapid antidepressant effect of ketamine in mice. Molecular Psychiatry 16,
1068–1070.
Boland, E. M., Rao, H., Dinges, D. F., Smith, R. V., Goel, N., Detre, J. A., et al. (2017). Meta-
analysis of the antidepressant effects of acute sleep deprivation. The Journal of
Clinical Psychiatry 78, e1020–e1034.
Borbély, A. A. (1982). A two process model of sleep regulation. Human Neurobiology 1,
195–204.
Borbély, A. A., Baumann, F., Brandeis, D., Strauch, I., & Lehmann, D. (1981). Sleep depriva-
tion: Effect on sleep stages and EEG power density in man. Electroencephalography
and Clinical Neurophysiology 51, 483–495.
Borbély, A. A., & Wirz-Justice, A. (1982). Sleep, sleep deprivation and depression. A hy-
pothesis derived from a model of sleep regulation. Human Neurobiology 1, 205–210.
Born, J., & Wilhelm, I. (2012). System consolidation of memory during sleep. Psychological
Research 76, 192–203.
Breier, A., Malhotra, A. K., Pinals, D. A., Weisenfeld, N. I., & Pickar, D. (1997). Association of
ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy
volunteers. American Journal of Psychiatry 154, 805–811.
Brüning, F., Noya, S. B., Bange, T., Koutsouli, S., Rudolph, J. D., Tyagarajan, S. K., et al.
(2019). Sleep-wake cycles drive daily dynamics of synaptic phosphorylation.
Science 366, eaav3617.
Bryant, P. A., Trinder, J., & Curtis, N. (2004). Sick and tired: does sleep have a vital role in
the immune system? Nature Reviews Immunology 4, 457–467.
Buijs, R. M., Kalsbeek, A., van der Woude, T. P., van Heerikhuize, J. J., & Shinn, S. (1993).
Suprachiasmatic nucleus lesion increases corticosterone secretion. The American
Journal of Physiology 264, R1186–R1192.
Bunney, B. G., & Bunney, W. E. (2012). Rapid-acting antidepressant strategies: Mecha-
nisms of action. The International Journal of Neuropsychopharmacology 15, 695–713.
Bunney, B. G., Li, J. Z., Walsh, D. M., Stein, R., Vawter, M. P., Cartagena, P., et al. (2015). Cir-
cadian dysregulation of clock genes: clues to rapid treatments in major depressive
disorder. Molecular Psychiatry 20, 48–55.
Campbell, I. G., & Feinberg, I. (1996). NREM delta stimulation following MK-801 is a re-
sponse of sleep systems. Journal of Neurophysiology 76, 3714–3720.
Canali, P., Papa, G. S., Casali, A. G., Schiena, G., Fecchio, M., Pigorini, A., et al. (2014).
Changes of cortical excitability as markers of antidepressant response in bipolar de-
pression : preliminary data obtained by combining transcranial magnetic stimulation
(TMS) and electroencephalography (EEG). Bipolar Disorders 16, 809–819.
Castrén, E., Võikar, V., & Rantamäki, T. (2007). Role of neurotrophic factors in depression.
Current Opinion in Pharmacology 7, 18–21.
Challet, E., Caldelas, I., Graff, C., & Pévet, P. (2003). Synchronization of themolecular clock-
work by light- and food-related cues in mammals. Biological Chemistry, 384.
Chambille, I. (1999). Circadian rhythm of AMPA receptor GluR2/3 subunit-immunoreac-
tivity in the suprachiasmatic nuclei of Syrian hamster and effect of a light–dark
cycle. Brain Research 833, 27–38.
Chang, L., Zhang, K., Pu, Y., Qu, Y., Ming, W. S., Xiong, Z., et al. (2019). Comparison of an-
tidepressant and side effects in mice after intranasal administration of (R,S)-keta-
mine, (R)-ketamine, and (S)-ketamine. Pharmacology Biochemistry and Behavior
181, 53–59.
Cirelli, C., & Tononi, G. (2020). Effects of sleep and waking on the synaptic ultrastructure.
Philosophical Transactions of the Royal Society B: Biological Sciences 375, 20190235.
Clemm von Hohenberg, C., Weber-Fahr, W., Lebhardt, P., Ravi, N., Braun, U., Gass, N., et al.
(2018). Lateral habenula perturbation reduces default-mode network connectivity in
a rat model of depression. Translational Psychiatry 8, 68.
Coogan, A. N., & Piggins, H. D. (2004). MAP kinases in the mammalian circadian system–
key regulators of clock function. Journal of Neurochemistry 90, 769–775.
Coyle, C. M., & Laws, K. R. (2015). The use of ketamine as an antidepressant: a systematic
review and meta-analysis: Ketamine as an antidepressant. Human
Psychopharmacology: Clinical and Experimental 30, 152–163.
Crawford, C. A., Moran, A. E., Baum, T. J., Apodaca, M. G., Montejano, N. R., Park, G. I., et al.
(2020). Effects of monoamine depletion on the ketamine-induced locomotor activity
of preweanling, adolescent, and adult rats: Sex and age differences. Behavioural Brain
Research 379, 112267.
Cuddapah, V. A., Zhang, S. L., & Sehgal, A. (2019). Regulation of the blood-brain barrier by
circadian rhythms and sleep. Trends in Neurosciences 42, 500–510.
Dash, M. B., Douglas, C. L., Vyazovskiy, V. V., Cirelli, C., & Tononi, G. (2009). Long-term ho-
meostasis of extracellular glutamate in the rat cerebral cortex across sleep and wak-
ing states. Journal of Neuroscience 29, 620–629.
De Bartolomeis, A., Sarappa, C., Buonaguro, E. F., Marmo, F., Eramo, A., Tomasetti, C., &
Iasevoli, F. (2013). Different effects of the NMDA receptor antagonists ketamine,
MK-801, and memantine on postsynaptic density transcripts and their topography:
Role of Homer signaling, and implications for novel antipsychotic and pro-cognitive
targets in psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry
46, 1–12.
S. Kohtala, O. Alitalo, M. Rosenholm et al. Pharmacology & Therapeutics 221 (2021) 107741De Coursey, P. J. (1960). Daily light sensitivity rhythm in a rodent. Science 131, 33–35.
Deboer, T. (2018). Sleep homeostasis and the circadian clock: Do the circadian pacemaker
and the sleep homeostat influence each other’s functioning? Neurobiology of Sleep
and Circadian Rhythms 5, 68–77.
Diekelmann, S., & Born, J. (2010). The memory function of sleep. Nature Reviews
Neuroscience 11, 114–126.
Diering, G. H., Nirujogi, R. S., Roth, R. H., Worley, P. F., Pandey, A., & Huganir, R. L. (2017).
Homer1a drives homeostatic scaling-down of excitatory synapses during sleep.
Science 355, 511–515.
Duman, R. S., & Aghajanian, G. K. (2012). Synaptic dysfunction in depression: potential
therapeutic targets. Science 338, 68–72.
Duman, R. S., Heninger, G. R., & Nestler, E. J. (1997). A molecular and cellular theory of de-
pression. Archives of General Psychiatry 54, 597–606.
Duncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., et al. (2013).
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plastic-
ity in major depressive disorder. The International Journal of Neuropsychopharma
cology 16, 301–311.
Duncan,W. C., Selter, J., Brutsche, N., Sarasso, S., & Zarate, C. A. (2013). Baseline delta sleep
ratio predicts acute ketamine mood response in major depressive disorder. Journal of
Affective Disorders 145, 115–119.
Duncan,W. C., Slonena, E., Hejazi, N. S., Brutsche, N., Yu, K. C., Park, L., et al. (2017). Motor-
activity markers of circadian timekeeping are related to ketamine’s rapid antidepres-
sant properties. Biological Psychiatry 82, 361–369.
Duncan, W. C., Slonena, E. E., Hejazi, N. S., Brutsche, N., Park, L. T., Henter, I. D., et al.
(2018). Are 24-hour motor activity patterns associated with continued rapid re-
sponse to ketamine? Neuropsychiatric Disease and Treatment 14, 2739–2748.
Duncan, W. C., & Zarate, C. A. (2013). Ketamine, sleep, and depression: Current status and
new questions. Current Psychiatry Reports 15, 394.
Durmer, J. S., & Dinges, D. F. (2005). Neurocognitive consequences of sleep deprivation.
Seminars in Neurology 25, 117–129.
Dwyer, J. M., Maldonado-Avilés, J. G., Lepack, A. E., DiLeone, R. J., & Duman, R. S. (2015).
Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive be-
havior. Proceedings of the National Academy of Sciences 112, 6188–6193.
Ebling, F. J. (1996). The role of glutamate in the photic regulation of the suprachiasmatic
nucleus. Progress in Neurobiology 50, 109–132.
Echizenya, M., Suda, H., Takeshima, M., Inomata, Y., & Shimizu, T. (2013). Total sleep dep-
rivation followed by sleep phase advance and bright light therapy in drug-resistant
mood disorders. Journal of Affective Disorders 144, 28–33.
Ehlers, C. L., Havstad, J. W., & Kupfer, D. J. (1996). Estimation of the time course of slow-
wave sleep over the night in depressed patients: effects of clomipramine and clinical
response. Biological Psychiatry 39, 171–181.
Eichhammer, P., Kharraz, A., Wiegand, R., Langguth, B., Frick, U., Aigner, J. M., & Hajak, G.
(2002). Sleep deprivation in depression. Life Sciences 70, 1741–1749.
Esser, S. K., Hill, S. L., & Tononi, G. (2007). Sleep homeostasis and cortical synchronization:
I. Modeling the effects of synaptic strength on sleep slowwaves. Sleep 30, 1617–1630.
Faraguna, U., Vyazovskiy, V. V., Nelson, A. B., Tononi, G., & Cirelli, C. (2008). A causal role
for brain-derived neurotrophic factor in the homeostatic regulation of sleep. The
Journal of Neuroscience 28, 4088–4095.
Farmer, C. A., Gilbert, J. R., Moaddel, R., George, J., Adeojo, L., Lovett, J., et al. (2020). Keta-
mine metabolites, clinical response, and gamma power in a randomized, placebo-
controlled, crossover trial for treatment-resistant major depression.
Neuropsychopharmacology 45, 1398–1404.
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena, S., et al.
(2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic
stress disorder: A randomized clinical trial. JAMA Psychiatry 71, 681.
Feinberg, I., & Campbell, I. G. (1993). Ketamine administration during waking increases
delta EEG intensity in rat sleep. Neuropsychopharmacology 9, 41–48.
Feinberg, I., & Campbell, I. G. (2010). Sleep EEG changes during adolescence: An index of a
fundamental brain reorganization. Brain and Cognition 72, 56–65.
Ficek, J., Zygmunt, M., Piechota, M., Hoinkis, D., Rodriguez Parkitna, J., Przewlocki, R., &
Korostynski, M. (2016). Molecular profile of dissociative drug ketamine in relation
to its rapid antidepressant action. BMC Genomics 17, 362.
Fogel, S., Martin, N., Lafortune, M., Barakat, M., Debas, K., Laventure, S., et al. (2012). NREM
sleep oscillations and brain plasticity in aging. Frontiers in Neurology 3, 176.
Fuchikami, M., Thomas, A., Liu, R., Wohleb, E. S., Land, B. B., DiLeone, R. J., et al. (2015).
Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and
sustained antidepressant actions. Proceedings of the National Academy of Sciences
112, 8106–8111.
Fukumoto, K., Fogaça, M. V., Liu, R. -J., Duman, C., Kato, T., Li, X. -Y., & Duman, R. S. (2019).
Activity-dependent brain-derived neurotrophic factor signaling is required for the
antidepressant actions of (2R,6R)-hydroxynorketamine. Proceedings of the National
Academy of Sciences 116, 297–302.
Gallego, M., & Virshup, D. M. (2007). Post-translational modifications regulate the ticking
of the circadian clock. Nature Reviews Molecular Cell Biology 8, 139–148.
Gangwisch, J. E., Heymsfield, S. B., Boden-Albala, B., Buijs, R. M., Kreier, F., Pickering, T. G.,
et al. (2006). Short sleep duration as a risk factor for hypertension: Analyses of the
first national health and nutrition examination survey. Hypertension 47, 833–839.
Germain, A., Nofzinger, E. A., Meltzer, C. C., Wood, A., Kupfer, D. J., Moore, R. Y., & Buysse,
D. J. (2007). Diurnal variation in regional brain glucose metabolism in depression.
Biological Psychiatry 62, 438–445.
Gerner, R. H., Post, R. M., Gillin, C., & Bunney, W. E. (1979). Biological and behavioral ef-
fects of one night’s sleep deprivation in depressed patients and normals. Journal of
Psychiatric Research 15, 21–40.
Ghosal, S., Bang, E., Yue, W., Hare, B. D., Lepack, A. E., Girgenti, M. J., & Duman, R. S. (2018).
Activity-dependent brain-derived neurotrophic factor release is required for the
rapid antidepressant actions of scopolamine. Biological Psychiatry 83, 29–37.14Giedt, W. R., Lakin, M. L., & Winters, W. D. (1978). Diurnal response to ketamine and
gamma-hydroxybutyrate and its possible relationship to pineal indoleamines.
Neuropharmacology 17, 221–228.
Giese, M., Beck, J., Brand, S., Muheim, F., Hemmeter, U., Hatzinger, M., et al. (2014). Fast
BDNF serum level increase and diurnal BDNF oscillations are associated with thera-
peutic response after partial sleep deprivation. Journal of Psychiatric Research 59, 1–7.
Gilbert, J. R., & Zarate, C. A. (2020). Electrophysiological biomarkers of antidepressant re-
sponse to ketamine in treatment-resistant depression: Gamma power and long-term
potentiation. Pharmacology, Biochemistry, and Behavior 189, 172856.
Ginty, D., Kornhauser, J., Thompson, M., Bading, H., Mayo, K., Takahashi, J., & Greenberg,
M. (1993). Regulation of CREB phosphorylation in the suprachiasmatic nucleus by
light and a circadian clock. Science 260, 238–241.
Göder, R., Hinrichsen, I., Seeck-Hirschner, M., Pfeiffer, R., Weinhold, S. L., Baier, P. C., et al.
(2016). Sleep at baseline and after electroconvulsive therapy in patients with major
depression. Psychiatry Research 246, 683–687.
Golombek, D. A., & Rosenstein, R. E. (2010). Physiology of circadian entrainment.
Physiological Reviews 90, 1063–1102.
Grunebaum, M. F., Galfalvy, H. C., Choo, T. -H., Parris, M. S., Burke, A. K., Suckow, R. F., et al.
(2019). Ketamine metabolite pilot study in a suicidal depression trial. Journal of
Psychiatric Research 117, 129–134.
Hanlon, E. C., Faraguna, U., Vyazovskiy, V. V., Tononi, G., & Cirelli, C. (2009). Effects of
skilled training on sleep slow wave activity and cortical gene expression in the rat.
Sleep 32, 719–729.
Hare, B. D., Shinohara, R., Liu, R. J., Pothula, S., DiLeone, R. J., & Duman, R. S. (2019).
Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid
and long-lasting antidepressant effects. Nature Communications 10, 223.
Hasler, B. P., Buysse, D. J., Kupfer, D. J., & Germain, A. (2010). Phase relationships between
core body temperature, melatonin, and sleep are associatedwith depression severity:
Further evidence for circadian misalignment in non-seasonal depression. Psychiatry
Research 178, 205–207.
Hastings, M. H., Duffield, G. E., Ebling, F. J., Kidd, A., Maywood, E. S., & Schurov, I. (1997).
Non-photic signalling in the suprachiasmatic nucleus. Biology of the Cell 89, 495–503.
Hastings, M. H., Duffield, G. E., Smith, E. J. D., Maywood, E. S., & Ebling, F. J. P. (1998). En-
trainment of the circadian system of mammals by nonphotic cues. Chronobiology
International 15, 425–445.
Hastings, M. H., & Herzog, E. D. (2004). Clock genes, oscillators, and cellular networks in
the suprachiasmatic nuclei. Journal of Biological Rhythms 19, 400–413.
Hawkins, J., Phillips, N., Moore, J. D., Gilliland, M. A., Dunbar, S., & Hicks, R. A. (1980). Emo-
tionality and REMD: A rat swimming model. Physiology and Behavior 25, 167–171.
He, J., Hsuchou, H., He, Y., Kastin, A. J., Wang, Y., & Pan,W. (2014). Sleep restriction impairs
blood-brain barrier function. The Journal of Neuroscience 34, 14697–14706.
Herzog, E. D., & Tosini, G. (2001). The mammalian circadian clock shop. Seminars in Cell &
Developmental Biology 12, 295–303.
Hill, J. L., Hardy, N. F., Jimenez, D. V., Maynard, K. R., Kardian, A. S., Pollock, C. J., et al.
(2016). Loss of promoter IV-driven BDNF expression impacts oscillatory activity dur-
ing sleep, sensory information processing and fear regulation. Translational Psychiatry
6, e873.
Hirano, A., Fu, Y. -H., & Ptáček, L. J. (2016). The intricate dance of post-translational mod-
ifications in the rhythm of life. Nature Structural & Molecular Biology 23, 1053–1060.
Holz, A., Mülsch, F., Schwarz, M. K., Hollmann, M., Döbrössy, M. D., Coenen, V. A., et al.
(2019). Enhanced mGlu5 signaling in excitatory neurons promotes rapid antidepres-
sant effects via AMPA receptor activation. Neuron 104, 338–352 (e7).
Homayoun, H., & Moghaddam, B. (2007). NMDA receptor hypofunction produces oppo-
site effects on prefrontal cortex interneurons and pyramidal neurons. The Journal of
Neuroscience 27, 11496–11500.
Hu, H., Cui, Y., & Yang, Y. (2020). Circuits and functions of the lateral habenula in health
and in disease. Nature Reviews Neuroscience 21(5), 277–295.
Hu, J. -H., Park, J. M., Park, S., Xiao, B., Dehoff, M. H., Kim, S., et al. (2010). Homeostatic scal-
ing requires group I mGluR activation mediated by Homer1a. Neuron 68, 1128–1142.
Huber, R., Deboer, T., & Tobler, I. (2000). Effects of sleep deprivation on sleep and sleep
EEG in three mouse strains: empirical data and simulations. Brain Research 857, 8–19.
Huber, R., Esser, S. K., Ferrarelli, F., Massimini, M., Peterson, M. J., & Tononi, G. (2007).
TMS-induced cortical potentiation during wakefulness locally increases slow wave
activity during sleep. PloS One 2, e276.
Huber, R., Ghilardi, M. F., Massimini, M., Ferrarelli, F., Riedner, B. A., Peterson, M. J., &
Tononi, G. (2006). Arm immobilization causes cortical plastic changes and locally de-
creases sleep slow wave activity. Nature Neuroscience 9, 1169–1176.
Huber, R., Mäki, H., Rosanova, M., Casarotto, S., Canali, P., Casali, A. G., et al. (2013). Human
cortical excitability increases with time awake. Cerebral Cortex 23, 332–338.
Huber, R., Tononi, G., & Cirelli, C. (2007). Exploratory behavior, cortical BDNF expression,
and sleep homeostasis. Sleep 30, 129–139.
Iitaka, C., Miyazaki, K., Akaike, T., & Ishida, N. (2005). A role for glycogen synthase kinase-
3β in the mammalian circadian clock. Journal of Biological Chemistry 280,
29397–29402.
Inokawa, H., Umemura, Y., Shimba, A., Kawakami, E., Koike, N., Tsuchiya, Y., et al. (2020).
Chronic circadian misalignment accelerates immune senescence and abbreviates
lifespan in mice. Scientific Reports 10, 2569.
Ishida, N., Matsui, M., Mitsui, Y., & Mishina, M. (1994). Circadian expression of NMDA re-
ceptor mRNAs, ε3 and ζ1, in the suprachiasmatic nucleus of rat brain. Neuroscience
Letters 166, 211–215.
Janik, D., & Mrosovsky, N. (1994). Intergeniculate leaflet lesions and behaviorally-induced
shifts of circadian rhythms. Brain Research 651, 174–182.
Ji, Y., Lu, Y., Yang, F., Shen, W., Tang, T. T. -T., Feng, L., et al. (2010). Acute and gradual in-
creases in BDNF concentration elicit distinct signaling and functions in neurons.
Nature Neuroscience 13, 302–309.
S. Kohtala, O. Alitalo, M. Rosenholm et al. Pharmacology & Therapeutics 221 (2021) 107741Kalmbach, D. A., Pillai, V., Cheng, P., Arnedt, J. T., & Drake, C. L. (2015). Shift work disorder,
depression, and anxiety in the transition to rotating shifts: the role of sleep reactivity.
Sleep Medicine 16, 1532–1538.
Karatsoreos, I. N., Bhagat, S., Bloss, E. B., Morrison, J. H., & McEwen, B. S. (2011). Disruption
of circadian clocks has ramifications for metabolism, brain, and behavior. Proceedings
of the National Academy of Sciences 108, 1657–1662.
Kato, A., Fukazawa, Y., Ozawa, F., Inokuchi, K., & Sugiyama, H. (2003). Activation of ERK
cascade promotes accumulation of Vesl-1S/Homer-1a immunoreactivity at synapses.
Molecular Brain Research 118, 33–44.
Kato, T., Fogaça, M. V., Deyama, S., Li, X. -Y., Fukumoto, K., & Duman, R. S. (2018). BDNF
release and signaling are required for the antidepressant actions of GLYX-13.
Molecular Psychiatry 23, 2007–2017.
Kattler, H., Dijk, D. J., & Borbély, A. A. (1994). Effect of unilateral somatosensory stimula-
tion prior to sleep on the sleep EEG in humans. Journal of Sleep Research 3, 159–164.
Khalsa, S. B. S., Jewett, M. E., Cajochen, C., & Czeisler, C. A. (2003). A phase response curve
to single bright light pulses in human subjects. The Journal of Physiology 549, 945–952.
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U.
(2016). Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate re-
ceptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy,
safety and time trajectories. Psychological Medicine 46, 1459–1472.
Kohtala, S., Theilmann, W., Rosenholm, M., Müller, H. K., Kiuru, P., Wegener, G., et al.
(2019). Ketamine-induced regulation of TrkB-GSK3β signaling is accompanied by
slow EEG oscillations and sedation but is independent of hydroxynorketamine me-
tabolites. Neuropharmacology 157, 107684.
Kohtala, S., Theilmann, W., Rosenholm, M., Penna, L., Karabulut, G., Uusitalo, S., et al.
(2019). Cortical excitability and activation of TrkB signaling during rebound slow os-
cillations are critical for rapid antidepressant responses. Molecular Neurobiology 56,
4163–4174.
Koike, H., Iijima, M., & Chaki, S. (2011). Involvement of AMPA receptor in both the rapid
and sustained antidepressant-like effects of ketamine in animalmodels of depression.
Behavioural Brain Research 224, 107–111.
Krout, K. E., Kawano, J., Mettenleiter, T. C., & Loewy, A. D. (2002). CNS inputs to the supra-
chiasmatic nucleus of the rat. Neuroscience 110, 73–92.
Krueger, J. M., Frank, M. G., Wisor, J. P., & Roy, S. (2016). Sleep function: Toward elucidat-
ing an enigma. Sleep Medicine Reviews 28, 46–54.
Kuhn, M., Mainberger, F., Feige, B., Maier, J. G., Mall, V., Jung, N. H., et al. (2016). State-de-
pendent partial occlusion of cortical LTP-like plasticity in major depression.
Neuropsychopharmacology 41, 1521–1529.
Kuhn, M., Wolf, E., Maier, J. G., Mainberger, F., Feige, B., Schmid, H., et al. (2016). Sleep
recalibrates homeostatic and associative synaptic plasticity in the human cortex.
Nature Communications 7, 12455.
Kupfer, D. J., Ehler, C. L., Frank, E., Grochocinski, V. J., McEachran, A. B., & Alhaji, B. (1994).
Persistent effects of antidepressants: EEG sleep studies in depressed patients during
maintenance treatment. Biological Psychiatry 35, 781–793.
Landgraf, D., Long, J. E., Proulx, C. D., Barandas, R., Malinow, R., & Welsh, D. K. (2016). Ge-
netic disruption of circadian rhythms in the suprachiasmatic nucleus causes helpless-
ness, behavioral despair, and anxiety-like behavior in mice. Biological Psychiatry 80,
827–835.
Langel, J., Ikeno, T., Yan, L., Nunez, A. A., & Smale, L. (2018). Distributions of GABAergic and
glutamatergic neurons in the brains of a diurnal and nocturnal rodent. Brain Research
1700, 152–159.
Lavie, P. (1997). Melatonin: Role in gating nocturnal rise in sleep propensity. Journal of
Biological Rhythms 12, 657–665.
Le Bon, O., Popa, D., Streel, E., Alexandre, C., Lena, C., Linkowski, P., & Adrien, J. (2007).
Ultradian cycles in mice: Definitions and links with REMS and NREMS. Journal of
Comparative Physiology 193, 1021–1032.
Lecca, S., Meye, F. J., & Mameli, M. (2014). The lateral habenula in addiction and depres-
sion: An anatomical, synaptic and behavioral overview. European Journal of
Neuroscience 39, 1170–1178.
Lee, B., Li, A., Hansen, K. F., Cao, R., Yoon, J. H., & Obrietan, K. (2010). CREB influences
timing and entrainment of the SCN circadian clock. Journal of Biological Rhythms 25,
410–420.
Lepack, A. E., Bang, E., Lee, B., Dwyer, J. M., & Duman, R. S. (2016). Fast-acting antidepres-
sants rapidly stimulate ERK signaling and BDNF release in primary neuronal cultures.
Neuropharmacology 111, 242–252.
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2014). BDNF release
is required for the behavioral actions of ketamine. The International Journal of
Neuropsychopharmacology 18, pyu033.
Levi, F., & Schibler, U. (2007). Circadian rhythms: Mechanisms and therapeutic implica-
tions. Annual Review of Pharmacology and Toxicology 47, 593–628.
Li, B., Piriz, J., Mirrione, M., Chung, C., Proulx, C. D., Schulz, D., ... Malinow, R. (2011). Syn-
aptic potentiation onto habenula neurons in the learned helplessness model of de-
pression. Nature 470, 535–539.
Li, C. -T., Chen, M. -H., Lin, W. -C., Hong, C. -J., Yang, B. -H., Liu, R. -S., et al. (2016). The ef-
fects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resis-
tant depression: A randomized controlled study. Human Brain Mapping 37,
1080–1090.
Li, J. Z., Bunney, B. G., Meng, F., Hagenauer, M. H., Walsh, D. M., Vawter, M. P., et al. (2013).
Circadian patterns of gene expression in the human brain and disruption inmajor de-
pressive disorder. Proceedings of the National Academy of Sciences 110, 9950–9955.
Li, N., Lee, B., Liu, R. -J., Banasr, M., Dwyer, J. M., Iwata, M., et al. (2010). mTOR-dependent
synapse formation underlies the rapid antidepressant effects of NMDA antagonists.
Science 329, 959–964.
Li, N., Liu, R. J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., et al. (2011). Glutamate N-methyl-
D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits
caused by chronic stress exposure. Biological Psychiatry 69, 754–761.15Li, W., Ma, L., Yang, G., & Gan,W. (2017). REM sleep selectively prunes andmaintains new
synapses in development and learning. Nature Neuroscience 20, 427–437.
Liu, A. C., Welsh, D. K., Ko, C. H., Tran, H. G., Zhang, E. E., Priest, A. A., et al. (2007). Inter-
cellular coupling confers robustness against mutations in the SCN circadian clock net-
work. Cell 129, 605–616.
Liu, R. -J., Lee, F. S., Li, X. -Y., Bambico, F., Duman, R. S., & Aghajanian, G. K. (2012). Brain-
derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated
synaptogenesis in prefrontal cortex. Biological Psychiatry 71, 996–1005.
Liu, Z. -W., Faraguna, U., Cirelli, C., Tononi, G., & Gao, X. -B. (2010). Direct evidence for
wake-related increases and sleep-related decreases in synaptic strength in rodent
cortex. Journal of Neuroscience 30, 8671–8675.
Lonze, B. E., & Ginty, D. D. (2002). Function and regulation of CREB family transcription
factors in the nervous system. Neuron 35, 605–623.
Lopez-Rodriguez, F., Kim, J., & Poland, R. E. (2004). Total sleep deprivation decreases im-
mobility in the forced-swim test. Neuropsychopharmacology 29, 1105–1111.
Lu, J., Nelson, L. E., Franks, N., Maze, M., Chamberlin, N. L., & Saper, C. B. (2008). Role of en-
dogenous sleep-wake and analgesic systems in anesthesia. Journal of Comparative
Neurology 508, 648–662.
Ly, J. Q. M., Gaggioni, G., Chellappa, S. L., Papachilleos, S., Brzozowski, A., Archer, S. N., et al.
(2016). Circadian regulation of human cortical excitability. Nature Communications 7,
11828.
Ma, Z., Zang, T., Birnbaum, S. G., Wang, Z., Johnson, J. E., Zhang, C. -L., & Parada, L. F. (2017).
TrkB dependent adult hippocampal progenitor differentiation mediates sustained ke-
tamine antidepressant response. Nature Communications 8, 1668.
Mackiewicz, M., Shockley, K. R., Romer, M. A., Galante, R. J., Zimmerman, J. E., Naidoo, N.,
et al. (2007). Macromolecule biosynthesis: A key function of sleep. Physiological
Genomics 31, 441–457.
Maeng, S., Zarate, C. A., Jr., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K.
(2008). Cellular mechanisms underlying the antidepressant effects of ketamine:
Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Biological Psychiatry 63, 349–352.
Mander, B. A., Santhanam, S., Saletin, J. M., & Walker, M. P. (2011). Wake deterioration
and sleep restoration of human learning. Current Biology 21, R183–R184.
Maret, S., Faraguna, U., Nelson, A. B., Cirelli, C., & Tononi, G. (2011). Sleep and waking
modulate spine turnover in the adolescent mouse cortex. Nature Neuroscience 14,
1418–1420.
Martinez-Lozano Sinues, P., Kohler, M., Brown, S. A., Zenobi, R., & Dallmann, R. (2017).
Gauging circadian variation in ketamine metabolism by real-time breath analysis.
Chemical Communications 53, 2264–2267.
Martiny, K., Refsgaard, E., Lund, V., Lunde, M., Sørensen, L., Thougaard, B., et al. (2013). The
day-to-day acute effect of wake therapy in patients with major depression using the
HAM-D6 as primary outcome measure: results from a randomised controlled trial.
PloS One 8, e67264.
Meijer, J. H., & Schwartz, W. J. (2003). In search of the pathways for light-induced pace-
maker resetting in the suprachiasmatic nucleus. Journal of Biological Rhythms 18,
235–249.
Mendez-David, I., Guilloux, J. -P., Papp, M., Tritschler, L., Mocaer, E., Gardier, A. M., et al.
(2017). S 47445 produces antidepressant- and anxiolytic-like effects through
neurogenesis dependent and independent mechanisms. Frontiers in Pharmacology 8,
462.
Mendoza, J. (2017). Circadian neurons in the lateral habenula: Clocking motivated behav-
iors. Pharmacology Biochemistry and Behavior 162, 55–61.
Miller, O. H., Moran, J. T., & Hall, B. J. (2016). Two cellular hypotheses explaining the ini-
tiation of ketamine’s antidepressant actions: Direct inhibition and disinhibition.
Neuropharmacology 100, 17–26.
Mintz, E. M., Marvel, C. L., Gillespie, C. F., Price, K. M., & Albers, H. E. (1999). Activation of
NMDA receptors in the suprachiasmatic nucleus produces light-like phase shifts of
the circadian clock in vivo. The Journal of Neuroscience 19, 5124–5130.
Moda-Sava, R. N., Murdock, M. H., Parekh, P. K., Fetcho, R. N., Huang, B. S., Huynh, T. N.,
et al. (2019). Sustained rescue of prefrontal circuit dysfunction by antidepressant-in-
duced spine formation. Science 364, eaat8078.
Moga, M. M., & Moore, R. Y. (1997). Organization of neural inputs to the suprachiasmatic
nucleus in the rat. The Journal of Comparative Neurology 389, 508–534.
Moore, R. Y., & Eichler, V. B. (1972). Loss of a circadian adrenal corticosterone rhythm fol-
lowing suprachiasmatic lesions in the rat. Brain Research 42, 201–206.
Morin, L. P., & Allen, C. N. (2006). The circadian visual system, 2005. Brain Research
Reviews 51, 1–60.
Mössner, L. D., Schmitz, A., Theurillat, R., Thormann,W., & Mevissen, M. (2011). Inhibition
of cytochrome P450 enzymes involved in ketamine metabolism by use of liver micro-
somes and specific cytochrome P450 enzymes from horses, dogs, and humans.
American Journal of Veterinary Research 72, 1505–1513.
Mrosovsky, N. (1996). Locomotor activity and non-photic influences on circadian clocks.
Biological Reviews 71(3), 343–372.
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., et al.
(2013). Antidepressant efficacy of ketamine in treatment-resistant major depression:
a two-site randomized controlled trial. The American Journal of Psychiatry 170,
1134–1142.
Nagele, P., Duma, A., Kopec, M., Gebara, M. A., Parsoei, A., Walker, M., et al. (2015). Nitrous
oxide for treatment-resistant major depression: A proof-of-concept trial. Biological
Psychiatry 78, 10–18.
Nakatsuka, H., & Natsume, K. (2014). Circadian rhythmmodulates long-term potentiation
induced at CA1 in rat hippocampal slices. Neuroscience Research 80, 1–9.
Nations, K. R., Dogterom, P., Bursi, R., Schipper, J., Greenwald, S., Zraket, D., et al. (2012).
Examination of Org 26576, an AMPA receptor positive allosteric modulator, in pa-
tients diagnosed with major depressive disorder: an exploratory, randomized, dou-
ble-blind, placebo-controlled trial. Journal of Psychopharmacology 26, 1525–1539.
S. Kohtala, O. Alitalo, M. Rosenholm et al. Pharmacology & Therapeutics 221 (2021) 107741Neumeister, A., Goessler, R., Lucht, M., Kapitany, T., Bamas, C., & Kasper, S. (1996). Bright
light therapy stabilizes the antidepressant effect of partial sleep deprivation.
Biological Psychiatry 39, 16–21.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., &
APA Council of Research Task Force on Novel Biomarkers and Treatments (2015). Ke-
tamine and other NMDA antagonists: Early clinical trials and possible mechanisms in
depression. The American Journal of Psychiatry 172, 950–966.
Nishiyama, J., & Yasuda, R. (2015). Biochemical computation for spine structural plasticity.
Neuron 87, 63–75.
Norimoto, H., Makino, K., Gao, M., Shikano, Y., Okamoto, K., Ishikawa, T., et al. (2018). Hip-
pocampal ripples down-regulate synapses. Science 359, 1524–1527.
Normann, C., Schmitz, D., Fürmaier, A., Döing, C., & Bach, M. (2007). Long-term plasticity
of visually evoked potentials in humans is altered in major depression. Biological
Psychiatry 62, 373–380.
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T.
(2013). Acute suppression of spontaneous neurotransmission drives synaptic poten-
tiation. The Journal of Neuroscience 33, 6990–7002.
Noya, S. B., Colameo, D., Brüning, F., Spinnler, A., Mircsof, D., Opitz, L., et al. (2019). The
forebrain synaptic transcriptome is organized by clocks but its proteome is driven
by sleep. Science 366, eaav2642.
Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C.
A. (2019). Ketamine has distinct electrophysiological and behavioral effects in de-
pressed and healthy subjects. Molecular Psychiatry 24, 1040–1052.
Nugent, A. C., Wills, K. E., Gilbert, J. R., & Zarate, C. A. (2019). Synaptic potentiation and
rapid antidepressant response to ketamine in treatment-resistant major depression:
A replication study. Psychiatry Research: Neuroimaging 283, 64–66.
Nutt, D., Wilson, S., & Paterson, L. (2008). Sleep disorders as core symptoms of depression.
Dialogues in Clinical Neuroscience 10, 329–336.
Obrietan, K., Impey, S., & Storm, D. R. (1998). Light and circadian rhythmicity regulate
MAP kinase activation in the suprachiasmatic nuclei. Nature Neuroscience 1, 693–700.
Ohayon, M. M., & Roth, T. (2003). Place of chronic insomnia in the course of depressive
and anxiety disorders. Journal of Psychiatric Research 37, 9–15.
Ohta, H., Yamazaki, S., & McMahon, D. G. (2005). Constant light desynchronizes mamma-
lian clock neurons. Nature Neuroscience 8, 267–269.
Olcese, U., Esser, S. K., & Tononi, G. (2010). Sleep and synaptic renormalization: A compu-
tational study. Journal of Neurophysiology 104, 3476–3493.
Orban, C., Kong, R., Li, J., Chee, M. W. L., & Yeo, B. T. T. (2020). Time of day is associated
with paradoxical reductions in global signal fluctuation and functional connectivity.
PloS Biology 18, e3000602.
Orozco-Solis, R., Montellier, E., Aguilar-Arnal, L., Sato, S., Vawter, M. P., Bunney, B. G., et al.
(2017). A circadian genomic signature common to ketamine and sleep deprivation in
the anterior cingulate cortex. Biological Psychiatry 82, 351–360.
Pace-Schott, E. F., & Hobson, J. A. (2002). The neurobiology of sleep: Genetics, cellular
physiology and subcortical networks. Nature Reviews Neuroscience 3, 591–605.
Park, H., & Poo, M. (2013). Neurotrophin regulation of neural circuit development and
function. Nature Reviews. Neuroscience 14, 7–23.
Partch, C. L., Green, C. B., & Takahashi, J. S. (2014). Molecular architecture of the mamma-
lian circadian clock. Trends in Cell Biology 24, 90–99.
Pavlides, C., Nivón, L. G., & McEwen, B. S. (2002). Effects of chronic stress on hippocampal
long-term potentiation: Effects of Stress on LTP. Hippocampus 12, 245–257.
Pennartz, C. M., Hamstra, R., & Geurtsen, A. M. (2001). Enhanced NMDA receptor activity
in retinal inputs to the rat suprachiasmatic nucleus during the subjective night. The
Journal of Physiology 532, 181–194.
Pennybaker, S. J., Niciu, M. J., Luckenbaugh, D. A., & Zarate, C. A. (2017). Symptomatology
and predictors of antidepressant efficacy in extended responders to a single ketamine
infusion. Journal of Affective Disorders 208, 560–566.
Pflug, B., & Tolle, R. (1971). Disturbance of the 24-hour rhythm in endogenous depression
and the treatment of endogenous depression by sleep deprivation. International
Pharmacopsychiatry 6, 187–196.
Pham, T. H., Defaix, C., Xu, X., Deng, S. X., Fabresse, N., Alvarez, J. C., et al. (2018). Common
neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine–
induced sustained antidepressant-like effects. Biological Psychiatry 84, e3–e6.
Phillips, D. J., Savenkova, M. I., & Karatsoreos, I. N. (2015). Environmental disruption of the
circadian clock leads to altered sleep and immune responses in mouse. Brain,
Behavior, and Immunity 47, 14–23.
Pickard, G. E. (1980). Morphological characteristics of retinal ganglion cells projecting to
the suprachiasmatic nucleus: a horseradish peroxidase study. Brain Research 183,
458–465.
Pittendrigh, C. S. (1988). The photoperiodic phenomena: seasonal modulation of the “day
within”. Journal of Biological Rhythms 3, 173–188.
Player, M. J., Taylor, J. L., Weickert, C. S., Alonzo, A., Sachdev, P., Martin, D., ... Loo, C. K.
(2013). Neuroplasticity in depressed individuals compared with healthy controls.
Neuropsychopharmacology 38, 2101–2108.
Quigg, M., Straume, M., Smith, T., Menaker, M., & Bertram, E. H. (2001). Seizures induce
phase shifts of rat circadian rhythms. Brain Research 913, 165–169.
Rantamäki, T., & Kohtala, S. (2020). Encoding, consolidation, and renormalization in de-
pression: synaptic homeostasis, plasticity, and sleep integrate rapid antidepressant
effects. Pharmacological Reviews 72, 439–465.
Rantamäki, T., & Yalcin, I. (2016). Antidepressant drug action - From rapid changes on
network function to network rewiring. Progress in Neuro-Psychopharmacology &
Biological Psychiatry 64, 285–292.
Rebuelto, M., Ambros, L., Montoya, L., & Bonafine, R. (2002). Treatment-time-dependent
difference of ketamine pharmacological response and toxicity in rats. Chronobiology
International 19, 937–945.16Rebuelto, M., Ambros, L., Waxman, S., & Montoya, L. (2004). Chronobiological study of the
pharmacological response of rats to combination ketamine–midazolam.
Chronobiology International 21, 591–600.
Refinetti, R., & Menaker, M. (1992). The circadian rhythm of body temperature. Physiology
& Behavior 51, 613–637.
Reimund, E. (1994). The free radical flux theory of sleep.Medical Hypotheses 43, 231–233.
Réus, G. Z., Abaleira, H. M., Titus, S. E., Arent, C. O., Michels, M., da Luz, J. R., et al. (2016).
Effects of ketamine administration on the phosphorylation levels of CREB and TrKB
and on oxidative damage after infusion of MEK inhibitor. Pharmacological Reports
68, 177–184.
Réus, G. Z., Vieira, F. G., Abelaira, H. M., Michels, M., Tomaz, D. B., dos Santos, M. A. B., et al.
(2014). MAPK signaling correlates with the antidepressant effects of ketamine.
Journal of Psychiatric Research 55, 15–21.
Richards, J., & Gumz, M. L. (2012). Advances in understanding the peripheral circadian
clocks. The FASEB Journal 26, 3602–3613.
Riedner, B. A., Vyazovskiy, V. V., Huber, R., Massimini, M., Esser, S., Murphy, M., & Tononi,
G. (2007). Sleep homeostasis and cortical synchronization: III. A high-density EEG
study of sleep slow waves in humans. Sleep 30, 1643–1657.
Riemann, D., Berger, M., & Voderholzer, U. (2001). Sleep and depression — Results from
psychobiological studies: An overview. Biological Psychology 57, 67–103.
Riemann, D., König, A., Hohagen, F., Kiemen, A., Voderholzer, U., Backhaus, J., et al. (1999).
How to preserve the antidepressive effect of sleep deprivation: A comparison of sleep
phase advance and sleep phase delay. European Archives of Psychiatry and Clinical
Neuroscience 249, 231–237.
Riemann, D., Krone, L. B., Wulff, K., & Nissen, C. (2020). Sleep, insomnia, and depression.
Neuropsychopharmacology 45, 74–89.
Rocha, R. B., Dondossola, E. R., Grande, A. J., Colonetti, T., Ceretta, L. B., Passos, I. C., et al.
(2016). Increased BDNF levels after electroconvulsive therapy in patients with
major depressive disorder: A meta-analysis study. Journal of Psychiatric Research 83,
47–53.
Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011). Rapid resolution of obses-
sions after an infusion of intravenous ketamine in a patient with treatment-resistant
obsessive-compulsive disorder: A case report. The Journal of Clinical Psychiatry 72,
567–569.
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., et al. (2013).
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder:
proof-of-concept. Neuropsychopharmacology 38, 2475–2483.
Ruben,M. D., Smith, D. F., FitzGerald, G. A., & Hogenesch, J. B. (2019). Dosing timematters.
Science 365, 547–549.
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D.,
et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring
one or several treatment steps: A STAR*D report. The American Journal of Psychiatry
163, 1905–1917.
Sackeim, H. A., Luber, B., Katzman, G. P., Moeller, J. R., Prudic, J., Devanand, D. P., & Nobler,
M. S. (1996). The effects of electroconvulsive therapy on quantitative electroenceph-
alograms. Relationship to clinical outcome. Archives of General Psychiatry 53,
814–824.
Sandor, P., & Shapiro, C. M. (1994). Sleep patterns in depression and anxiety: Theory and
pharmacological effects. Journal of Psychosomatic Research 38, 125–139.
Sato, M., Suzuki, K., & Nakanishi, S. (2001). NMDA receptor stimulation and brain-derived
neurotrophic factor upregulate homer 1amRNA via themitogen-activated protein ki-
nase cascade in cultured cerebellar granule cells. The Journal of Neuroscience 21,
3797–3805.
Sato, Y., Kobayashi, E., Hakamata, Y., Kobahashi, M., Wainai, T., Murayama, T., et al. (2004).
Chronopharmacological studies of ketamine in normal and NMDA epsilon1 receptor
knockout mice. British Journal of Anaesthesia 92, 859–864.
Scharf, M. T., Naidoo, N., Zimmerman, J. E., & Pack, A. I. (2008). The energy hypothesis of
sleep revisited. Progress in Neurobiology 86, 264–280.
Seibt, J., & Frank, M. G. (2019). Primed to sleep: The dynamics of synaptic plasticity across
brain states. Frontiers in Systems Neuroscience 13, 2.
Serchov, T., Clement, H. -W., Schwarz, M. K., Iasevoli, F., Tosh, D. K., Idzko, M., et al. (2015).
Increased signaling via adenosine a1 receptors, sleep deprivation, imipramine, and
ketamine inhibit depressive-like behavior via induction of Homer. Neuron 87,
549–562.
Shen, M., Lv, D., Li, S., Zhang, Y., Wang, Z., Zhao, C., et al. (2019). Positive allosteric modu-
lation of AMPAR by PF-4778574 produced rapid onset antidepressant actions inmice.
Cerebral Cortex 29, 4438–4451.
Song, M., Martinowich, K., & Lee, F. S. (2017). BDNF at the synapse:Why location matters.
Molecular Psychiatry 22, 1370–1375.
Spano, G. M., Banningh, S. W., Marshall, W., de Vivo, L., Bellesi, M., Loschky, S. S., et al.
(2019). Sleep deprivation by exposure to novel objects increases synapse density
and axon–spine interface in the hippocampal CA1 region of adolescent mice. The
Journal of Neuroscience 39, 6613–6625.
Spiegel, K., Leproult, R., & Van Cauter, E. (1999). Impact of sleep debt onmetabolic and en-
docrine function. The Lancet 354, 1435–1439.
Stephan, F. K., & Zucker, I. (1972). Circadian rhythms in drinking behavior and locomotor
activity of rats are eliminated by hypothalamic lesions. Proceedings of the National
Academy of Sciences 69, 1583–1586.
Stickgold, R. (2005). Sleep-dependent memory consolidation. Nature 437, 1272–1278.
Stojkovic, K., Wing, S. S., & Cermakian, N. (2014). A central role for ubiquitination within a
circadian clock protein modification code. Frontiers in Molecular Neuroscience 7, 69.
Sumner, R. L., McMillan, R., Spriggs, M. J., Campbell, D., Malpas, G., Maxwell, E., et al.
(2020). Ketamine enhances visual sensory evoked potential long-term potentiation
in patients with major depressive disorder. Biological Psychiatry: Cognitive
Neuroscience and Neuroimaging 5, 45–55.
S. Kohtala, O. Alitalo, M. Rosenholm et al. Pharmacology & Therapeutics 221 (2021) 107741Sun, H. -L., Zhou, Z. -Q., Zhang, G. -F., Yang, C., Wang, X. -M., Shen, J. -C., et al. (2016). Role
of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic
unpredictable mild stress model. Translational Psychiatry 6, e741.
Szuba, M. P., Baxter, L. R., Altshuler, L. L., Allen, E. M., Guze, B. H., Schwartz, J. M., & Liston,
E. H. (1994). Lithium sustains the acute antidepressant effects of sleep deprivation:
Preliminary findings from a controlled study. Psychiatry Research 51, 283–295.
Takahashi, J. S. (2017). Transcriptional architecture of the mammalian circadian clock.
Nature Reviews. Genetics 18, 164–179.
Takahashi, J. S., & Zatz, M. (1982). Regulation of circadian rhythmicity. Science 217,
1104–1111.
Tononi, G., & Cirelli, C. (2003). Sleep and synaptic homeostasis: A hypothesis. Brain
Research Bulletin 62, 143–150.
Tononi, G., & Cirelli, C. (2012). Time to be SHY? Some comments on sleep and synaptic
homeostasis. Neural Plasticity 2012, 1–12.
Tononi, G., & Cirelli, C. (2014). Sleep and the price of plasticity: From synaptic and cellular
homeostasis to memory consolidation and integration. Neuron 81, 12–34.
Tononi, G., & Cirelli, C. (2020). Sleep and synaptic down-selection. European Journal of
Neuroscience 51, 413–421.
Travnickova-Bendova, Z., Cermakian, N., Reppert, S. M., & Sassone-Corsi, P. (2002). Bi-
modal regulation of mPeriod promoters by CREB-dependent signaling and CLOCK/
BMAL1 activity. Proceedings of the National Academy of Sciences 99, 7728–7733.
Tsuno, N., Besset, A., & Ritchie, K. (2005). Sleep and depression. The Journal of Clinical
Psychiatry 66, 1254–1269.
Usun, Y., Eybrard, S., Meyer, F., & Louilot, A. (2013). Ketamine increases striatal dopamine
release and hyperlocomotion in adult rats after postnatal functional blockade of the
prefrontal cortex. Behavioural Brain Research 256, 229–237.
Van Cauter, E., & Turek, F. W. (1986). Depression: A disorder of timekeeping? Perspectives
in Biology and Medicine 29, 510–520.
Van Dongen, H. P. A., Maislin, G., Mullington, J. M., & Dinges, D. F. (2003). The cumulative
cost of additional wakefulness: Dose-response effects on neurobehavioral functions
and sleep physiology from chronic sleep restriction and total sleep deprivation.
Sleep 26, 117–126.
Van Luijtelaar, E. L. J. M., & Coenen, A. M. L. (1985). Paradoxical sleep deprivation and the
immobility response in the rat: Effects of desipramine and phentolamine. Sleep 8,
49–55.
de Vivo, L., Bellesi, M., Marshall, W., Bushong, E. A., Ellisman, M. H., Tononi, G., & Cirelli, C.
(2017). Ultrastructural evidence for synaptic scaling across the wake/sleep cycle.
Science 355, 507–510.
Vyazovskiy, V. V., Cirelli, C., Pfister-Genskow,M., Faraguna, U., & Tononi, G. (2008). Molec-
ular and electrophysiological evidence for net synaptic potentiation in wake and de-
pression in sleep. Nature Neuroscience 11, 200–208.
Vyazovskiy, V. V., Olcese, U., Lazimy, Y. M., Faraguna, U., Esser, S. K., Williams, J. C., et al.
(2009). Cortical firing and sleep homeostasis. Neuron 63, 865–878.
Walker, M. P. (2009). The role of sleep in cognition and emotion. Annals of the New York
Academy of Sciences 1156, 168–197.
Walker, M. P., & Stickgold, R. (2006). Sleep, memory, and plasticity. Annual Review of
Psychology 57, 139–166.
Wang, T. A., Yu, Y. V., Govindaiah, G., Ye, X., Artinian, L., Coleman, T. P., et al. (2012). Cir-
cadian rhythm of redox state regulates excitability in suprachiasmatic nucleus neu-
rons. Science 337, 839–842.
Wang, X. -L., Yuan, K., Zhang, W., Li, S. -X., Gao, G. F., & Lu, L. (2020). Regulation of circa-
dian genes by the MAPK pathway: Implications for rapid antidepressant action.
Neuroscience Bulletin 36, 66–76.
West, A. E., Chen, W. G., Dalva, M. B., Dolmetsch, R. E., Kornhauser, J. M., Shaywitz, A. J.,
et al. (2001). Calcium regulation of neuronal gene expression. Proceedings of the
National Academy of Sciences 98, 11024–11031.
Widman, A. J., & McMahon, L. L. (2018). Disinhibition of CA1 pyramidal cells by low-dose
ketamine and other antagonists with rapid antidepressant efficacy. Proceedings of the
National Academy of Sciences 115, 201718883.
Winkler, D., Spies, M., Al-Resheg, Y., Wu, J. C., Bunney, W. E., Bunney, B. G., et al. (2019).
Usage of therapeutic sleep deprivation: A survey in psychiatric hospitals in Austria,
Germany, and Switzerland. Behavioral Sleep Medicine 17, 713–720.
Wirz-Justice, A., & Van den Hoofdakker, R. H. (1999). Sleep deprivation in depression:
What do we know, where do we go? Biological Psychiatry 46, 445–453.
Wisor, J. P., Pasumarthi, R. K., Gerashchenko, D., Thompson, C. L., Pathak, S., Sancar, A.,
et al. (2008). Sleep deprivation effects on circadian clock gene expression in the cere-
bral cortex parallel electroencephalographic differences among mouse strains. The
Journal of Neuroscience 28, 7193–7201.
Wolf, E., Kuhn, M., Norman, C., Mainberger, F., Maier, J. G., Maywald, S., et al. (2016). Syn-
aptic plasticity model of therapeutic sleep deprivation in major depression. Sleep
Medicine Reviews 30, 53–62.17Wotus, C., Lilley, T. R., Neal, A. S., Suleiman, N. L., Schmuck, S. C., Smarr, B. L., et al. (2013).
Forced desynchrony reveals independent contributions of suprachiasmatic oscillators
to the daily plasma corticosterone rhythm in male rats. PloS One 8, e68793.
Wray, N. H., Schappi, J. M., Singh, H., Senese, N. B., & Rasenick, M. M. (2019). NMDAR-in-
dependent, cAMP-dependent antidepressant actions of ketamine. Molecular
Psychiatry 24, 1833–1843.
Wu, J. C., Kelsoe, J. R., Schachat, C., Bunney, B. G., DeModena, A., Golshan, S., et al. (2009).
Rapid and sustained antidepressant response with sleep deprivation and chronother-
apy in bipolar disorder. Biological Psychiatry 66, 298–301.
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., et al. (2013). Sleep drivesme-
tabolite clearance from the adult brain. Science 342, 373–377.
Yamaguchi, J. -I., Toki, H., Qu, Y., Yang, C., Koike, H., Hashimoto, K., et al. (2018). (2R,6R)-
Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine
in mice. Neuropsychopharmacology 43, 1900–1907.
Yamamoto, T., Nakayama, T., Yamaguchi, J., Matsuzawa, M., Mishina, M., Ikeda, K., &
Yamamoto, H. (2016). Role of the NMDA receptor GluN2D subunit in the expression
of ketamine-induced behavioral sensitization and region-specific activation of neuro-
nal nitric oxide synthase. Neuroscience Letters 610, 48–53.
Yamazaki, S. (2000). Resetting central and peripheral circadian oscillators in transgenic
rats. Science 288, 682–685.
Yang, C., Qu, Y., Abe, M., Nozawa, D., Chaki, S., & Hashimoto, K. (2017). (R)-Ketamine
shows greater potency and longer lasting antidepressant effects than its metabolite
(2R,6R)-hydroxynorketamine. Biological Psychiatry 82, e43–e44.
Yang, G., & Gan, W. -B. (2012). Sleep contributes to dendritic spine formation and elimi-
nation in the developing mouse somatosensory cortex. Developmental Neurobiology
72, 1391–1398.
Yang, G., Lai, C. S. W., Cichon, J., Ma, L., Li, W., & Gan, W. -B. (2014). Sleep promotes
branch-specific formation of dendritic spines after learning. Science 344, 1173–1178.
Yang, Y., Cui, Y., Sang, K., Dong, Y., Ni, Z., Ma, S., & Hu, H. (2018). Ketamine blocks bursting
in the lateral habenula to rapidly relieve depression. Nature 554, 317–322.
Yoo, S. -H., Yamazaki, S., Lowrey, P. L., Shimomura, K., Ko, C. H., Buhr, E. D., et al. (2004).
PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent
circadian oscillations in mouse peripheral tissues. Proceedings of the National
Academy of Sciences 101, 5339–5346.
Zada, D., Bronshtein, I., Lerer-Goldshtein, T., Garini, Y., & Appelbaum, L. (2019). Sleep in-
creases chromosome dynamics to enable reduction of accumulating DNA damage
in single neurons. Nature Communications 10, 895.
Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant.
Molecular Psychiatry 23, 801–811.
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., et al. (2019).
(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant ac-
tions. Proceedings of the National Academy of Sciences 116, 6441–6450.
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., et al. (2016).
NMDAR inhibition-independent antidepressant actions of ketamine metabolites.
Nature 533, 481–486.
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., et al. (2018).
Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mecha-
nisms. Pharmacological Reviews 70, 621–660.
Zarate, C. A., Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., et al.
(2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-re-
sistant major depression. Archives of General Psychiatry 63, 856–864.
Zheng, W., Cai, D. -B., Xiang, Y. -Q., Zheng, W., Jiang, W. -L., Sim, K., et al. (2020). Adjunc-
tive intranasal esketamine for major depressive disorder: A systematic review of ran-
domized double-blind controlled-placebo studies. Journal of Affective Disorders 265,
63–70.
Zhou, H. -X., Chen, X., Shen, Y. -Q., Li, L., Chen, N. -X., Zhu, Z. -C., et al. (2020). Rumination
and the default mode network: Meta-analysis of brain imaging studies and implica-
tions for depression. NeuroImage 206, 116287.
Zhou, W., Wang, N., Yang, C., Li, X. -M., Zhou, Z. -Q., & Yang, J. -J. (2014). Ketamine-in-
duced antidepressant effects are associated with AMPA receptors-mediated upregu-
lation of mTOR and BDNF in rat hippocampus and prefrontal cortex. European
Psychiatry 29, 419–423.
Zhuo, C., Tian, H., Li, G., Chen, M., Jiang, D., Lin, X., et al. (2019). Effects of ketamine on cir-
cadian rhythm and synaptic homeostasis in patients with treatment-resistant de-
pression: A protocol for mechanistic studies of its rapid and sustained
antidepressant actions in humans. Brain and Behavior 9, e01423.
